
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Advances in Positron Emission Tomography/Computed Tomography for Diagnosing and Managing Primary Posterior Uveal Melanoma - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4B1498AF349B305B149003980A900.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="medscimon">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377407/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Medical Science Monitor: International Medical Journal of Experimental and Clinical Research">
<meta name="citation_title" content="Advances in Positron Emission Tomography/Computed Tomography for Diagnosing and Managing Primary Posterior Uveal Melanoma">
<meta name="citation_author" content="Iwona Obuchowska">
<meta name="citation_author_institution" content="Department of Ophthalmology, Medical University of Białystok, Białystok, Poland">
<meta name="citation_author" content="Diana Anna Dmuchowska">
<meta name="citation_author_institution" content="Department of Ophthalmology, Medical University of Białystok, Białystok, Poland">
<meta name="citation_author" content="Joanna Konopińska">
<meta name="citation_author_institution" content="Department of Ophthalmology, Medical University of Białystok, Białystok, Poland">
<meta name="citation_publication_date" content="2025 Aug 19">
<meta name="citation_volume" content="31">
<meta name="citation_firstpage" content="e949252">
<meta name="citation_doi" content="10.12659/MSM.949252">
<meta name="citation_pmid" content="40826825">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377407/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377407/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377407/pdf/medscimonit-31-e949252.pdf">
<meta name="description" content="Uveal melanoma is a common primary intra-ocular malignancy in adults. It is a highly aggressive cancer that can spread to other regions of the body. Thus, early detection and appropriate treatment are critical for patient survival. Currently, we ...">
<meta name="og:title" content="Advances in Positron Emission Tomography/Computed Tomography for Diagnosing and Managing Primary Posterior Uveal Melanoma">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Uveal melanoma is a common primary intra-ocular malignancy in adults. It is a highly aggressive cancer that can spread to other regions of the body. Thus, early detection and appropriate treatment are critical for patient survival. Currently, we ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377407/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12377407">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.12659/MSM.949252"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/medscimonit-31-e949252.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12377407%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12377407/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12377407/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377407/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-medscimon.png" alt="Medical Science Monitor: International Medical Journal of Experimental and Clinical Research logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Medical Science Monitor: International Medical Journal of Experimental and Clinical Research" title="Link to Medical Science Monitor: International Medical Journal of Experimental and Clinical Research" shape="default" href="https://www.medscimonit.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Med Sci Monit</button></div>. 2025 Aug 19;31:e949252. doi: <a href="https://doi.org/10.12659/MSM.949252" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.12659/MSM.949252</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Med%20Sci%20Monit%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Med%20Sci%20Monit%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Med%20Sci%20Monit%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Med%20Sci%20Monit%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Advances in Positron Emission Tomography/Computed Tomography for Diagnosing and Managing Primary Posterior Uveal Melanoma</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Obuchowska%20I%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Iwona Obuchowska</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Iwona Obuchowska</span></h3>
<div class="p">
<sup>1</sup>Department of Ophthalmology, Medical University of Białystok, Białystok, Poland</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Obuchowska%20I%22%5BAuthor%5D" class="usa-link"><span class="name western">Iwona Obuchowska</span></a>
</div>
</div>
<sup>1,</sup><sup>A,</sup><sup>B,</sup><sup>C,</sup><sup>D,</sup><sup>E,</sup><sup>F</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dmuchowska%20DA%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Diana Anna Dmuchowska</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Diana Anna Dmuchowska</span></h3>
<div class="p">
<sup>1</sup>Department of Ophthalmology, Medical University of Białystok, Białystok, Poland</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dmuchowska%20DA%22%5BAuthor%5D" class="usa-link"><span class="name western">Diana Anna Dmuchowska</span></a>
</div>
</div>
<sup>1,</sup><sup>D,</sup><sup>E</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Konopi%C5%84ska%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Joanna Konopińska</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Joanna Konopińska</span></h3>
<div class="p">
<sup>1</sup>Department of Ophthalmology, Medical University of Białystok, Białystok, Poland</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Konopi%C5%84ska%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Joanna Konopińska</span></a>
</div>
</div>
<sup>1,</sup><sup>E,</sup><sup>F,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="af1-medscimonit-31-e949252">
<sup>1</sup>Department of Ophthalmology, Medical University of Białystok, Białystok, Poland</div>
<div class="author-notes p">
<div class="fn" id="c1-medscimonit-31-e949252">
<sup>✉</sup><p class="display-inline">Corresponding Author: Joanna Konopińsk, e-mail: <span>joannakonopinska@o2.pl</span></p>
</div>
<div class="fn" id="fn1-medscimonit-31-e949252">
<sup>A</sup><p class="display-inline">Study Design</p>
</div>
<div class="fn" id="fn2-medscimonit-31-e949252">
<sup>B</sup><p class="display-inline">Data Collection</p>
</div>
<div class="fn" id="fn3-medscimonit-31-e949252">
<sup>C</sup><p class="display-inline">Statistical Analysis</p>
</div>
<div class="fn" id="fn4-medscimonit-31-e949252">
<sup>D</sup><p class="display-inline">Data Interpretation</p>
</div>
<div class="fn" id="fn5-medscimonit-31-e949252">
<sup>E</sup><p class="display-inline">Manuscript Preparation</p>
</div>
<div class="fn" id="fn6-medscimonit-31-e949252">
<sup>F</sup><p class="display-inline">Literature Search</p>
</div>
<div class="fn" id="fn7-medscimonit-31-e949252">
<sup>G</sup><p class="display-inline">Funds Collection</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Jul 10; Accepted 2025 May 23; Prepublished 2025 Apr 5; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© Med Sci Monit, 2025</div>
<p>This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (<a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">CC BY-NC-ND 4.0</a>)</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12377407  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40826825/" class="usa-link">40826825</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Uveal melanoma is a common primary intra-ocular malignancy in adults. It is a highly aggressive cancer that can spread to other regions of the body. Thus, early detection and appropriate treatment are critical for patient survival.</p>
<p>Currently, we cannot imagine modern oncological diagnostics without positron emission tomography/computed tomography (PET/CT). Although PET/CT is commonly used in cancer care, it is not widely used for eye cancer. However, as technology advances, more eye specialists are using PET/CT to stage tumors before treatment, to predict how patients will respond to treatment, and to monitor their progress to assess treatment effectiveness. In this review, we cover the aspects of this technology in managing posterior uveal melanoma and describe the advantages of PET/CT in providing better information about tumors and their responses to applied treatment. We also describe the role of PET/CT in distinguishing among posterior uveal melanomas, benign lesions such choroidal nevus, and other primary or metastatic intra-ocular malignancies. We also discuss the role of PET/CT in staging metastatic choroidal melanoma. As technology continues to evolve, the role of PET/CT in comprehensive management of eye cancer is likely to expand, offering enhanced insights into tumor characteristics and treatment outcomes.</p>
<p>This article reviews the role of PET/CT in diagnosing, staging, and monitoring treatment outcomes in patients with primary posterior uveal (choroidal and ciliary body) melanoma.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> Melanoma, Uveal Melanoma, Positron Emission Tomography Computed Tomography</p></section></section><section id="sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p>Posterior uveal melanoma is the most common type of primary intra-ocular malignancy in adults. It is a highly aggressive tumor with a high risk of distant metastasis. The AJCC classification of posterior uveal melanoma (choroidal and ciliary body) has an essential role in establishing prognosis and staging of melanoma [<a href="#b1-medscimonit-31-e949252" class="usa-link" aria-describedby="b1-medscimonit-31-e949252">1</a>]. Early detection of posterior uveal melanoma and implementation of appropriate treatments are critical for patient survival. Given the intra-ocular location of uveal melanoma, its detection on routine ophthalmological examination can sometimes be challenging, making it difficult to distinguish it from an easily detectable cutaneous melanoma. This places particular emphasis on various imaging techniques, both those specific to ophthalmology and general radiological methods, for detecting choroidal melanomas. The array of methods that have been used in ophthalmology for years, including ultrasonography and fluorescein and indocyanine green angiography, has recently expanded into relatively novel and minimally invasive techniques, such as optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA). However, conventional computed tomography (CT) and magnetic resonance imaging (MRI) still play important roles in evaluating choroidal melanoma, particularly in cases of extra-ocular extension [<a href="#b2-medscimonit-31-e949252" class="usa-link" aria-describedby="b2-medscimonit-31-e949252">2</a>].</p>
<p>Although positron emission tomography/computed tomography (PET/CT) plays a vital role in oncology, it is rarely used to detect or monitor ocular neoplasms. However, with technological progress and the growing availability of PET/CT, this method has been increasingly used in ophthalmic oncology [<a href="#b3-medscimonit-31-e949252" class="usa-link" aria-describedby="b3-medscimonit-31-e949252">3</a>–<a href="#b5-medscimonit-31-e949252" class="usa-link" aria-describedby="b5-medscimonit-31-e949252">5</a>]. PET/CT appears to be particularly useful for determining the tumor stage before treatment, establishing prognosis, and monitoring treatment outcomes.</p>
<p>This article reviews the role of PET/CT in diagnosis, staging, and monitoring treatment outcomes in patients with primary posterior uveal (choroidal and ciliary body) melanoma.</p></section><section id="sec2"><h2 class="pmc_sec_title">Posterior Uveal Melanoma</h2>
<section id="sec3"><h3 class="pmc_sec_title">Posterior Uveal Melanoma – Incidence and Clinical Characteristics</h3>
<p>Posterior uveal melanoma is a highly aggressive intra-ocular neoplasm found in adults, and it is derived from choroidal melanocytes. The choroid is a highly vascularized tissue that forms the intermediate layer of the eye and is primarily responsible for nourishing the underlying retina. Uveal melanoma accounts for 3–5% of all melanomas [<a href="#b6-medscimonit-31-e949252" class="usa-link" aria-describedby="b6-medscimonit-31-e949252">6</a>], with 98% of cases diagnosed in Whites. The prevalence of uveal melanoma is estimated at 5.1–6 cases per million in the United States and 6–7.5 cases per million in Europe [<a href="#b7-medscimonit-31-e949252" class="usa-link" aria-describedby="b7-medscimonit-31-e949252">7</a>–<a href="#b9-medscimonit-31-e949252" class="usa-link" aria-describedby="b9-medscimonit-31-e949252">9</a>].</p>
<p>Although uveal melanoma can develop in adults of any age, it is most frequently diagnosed in patients aged 58–60 years, and slightly more often in men than in women [<a href="#b10-medscimonit-31-e949252" class="usa-link" aria-describedby="b10-medscimonit-31-e949252">10</a>,<a href="#b11-medscimonit-31-e949252" class="usa-link" aria-describedby="b11-medscimonit-31-e949252">11</a>]. Only 1% of uveal melanomas are detected in patients aged &lt;20 years, with the remaining 99% found in those aged ≥21 years. Uveal melanoma in children is very rare [<a href="#b12-medscimonit-31-e949252" class="usa-link" aria-describedby="b12-medscimonit-31-e949252">12</a>,<a href="#b13-medscimonit-31-e949252" class="usa-link" aria-describedby="b13-medscimonit-31-e949252">13</a>].</p>
<p>Although the exact underlying mechanism of uveal melanoma development is unknown, the role of oxidative damage to the pigmented tissue of the eye has been emphasized, with the latter being modulated by the type and degree of pigmentation. Although uveal melanoma can develop within a pre-existing benign mass or choroidal nevus, recent evidence suggests that the risk of such a malignant transformation is low [<a href="#b6-medscimonit-31-e949252" class="usa-link" aria-describedby="b6-medscimonit-31-e949252">6</a>,<a href="#b14-medscimonit-31-e949252" class="usa-link" aria-describedby="b14-medscimonit-31-e949252">14</a>]. Recently, the role of genetics has been highlighted in the development of uveal melanoma. Eyes with uveal melanoma have been shown to harbor mutations in chromosomes 1,3,6, and 8 [<a href="#b15-medscimonit-31-e949252" class="usa-link" aria-describedby="b15-medscimonit-31-e949252">15</a>,<a href="#b16-medscimonit-31-e949252" class="usa-link" aria-describedby="b16-medscimonit-31-e949252">16</a>]. Chromosome 3 monosomy has been observed in 50–60% of aggressive uveal melanomas. Risk factors for uveal melanoma include choroidal nevi, freckles, light eye color, abnormal skin nevi, ota nevus, ocular melanocytosis, ultraviolet exposure, sun exposure, and outdoor activities [<a href="#b14-medscimonit-31-e949252" class="usa-link" aria-describedby="b14-medscimonit-31-e949252">14</a>].</p>
<p>The management of uveal melanomas depends on their location in the eye. Tumors are located at the periphery of the fundus outside the visual axis, and small lesions are usually asymptomatic in the early stages. Melanomas located closer to the macula and posterior pole of the eye, as well as large tumors and those associated with exudative retinal detachment, manifest with blurry vision, flashes, floaters, metamorphopsia, and visual field defects. Retinal detachment is more often observed in uveal melanomas &gt;4 mm [<a href="#b14-medscimonit-31-e949252" class="usa-link" aria-describedby="b14-medscimonit-31-e949252">14</a>].</p>
<p>Uveal melanoma presents as a dome-shaped (75%), mushroom-shaped (20%), or diffuse mass (5%) [<a href="#b7-medscimonit-31-e949252" class="usa-link" aria-describedby="b7-medscimonit-31-e949252">7</a>]. While most uveal melanomas are pigmented (55%), amelanotic (15%) and mixed lesions (30%) have been reported [<a href="#b10-medscimonit-31-e949252" class="usa-link" aria-describedby="b10-medscimonit-31-e949252">10</a>]. Depending on cellular architecture, uveal melanomas are classified as epithelioid cells (&gt;90% epithelioid cells), spindle cells (&gt;90% spindle cells), or mixed lesions (&gt;10% epithelioid cells and &lt;90% spindle cells) [<a href="#b17-medscimonit-31-e949252" class="usa-link" aria-describedby="b17-medscimonit-31-e949252">17</a>].</p>
<p>At the time of diagnosis of uveal melanoma, the average basal tumor diameter is 11.3 mm, with a mean thickness of 4*–5 mm [<a href="#b7-medscimonit-31-e949252" class="usa-link" aria-describedby="b7-medscimonit-31-e949252">7</a>,<a href="#b18-medscimonit-31-e949252" class="usa-link" aria-describedby="b18-medscimonit-31-e949252">18</a>]. Depending on their diameters, uveal melanomas are classified as small (4–8 mm diameter and/or 1–2.4 mm thickness), medium (6–16 mm diameter and/or 2.5–10 mm thickness), or large (&gt;16 mm diameter and/or &gt;10 mm thickness) [<a href="#b14-medscimonit-31-e949252" class="usa-link" aria-describedby="b14-medscimonit-31-e949252">14</a>]. Tumors with large basal diameters have a high risk of metastatic spread, and smaller tumors are associated with improved survival rate and increasing incidence rate [<a href="#b19-medscimonit-31-e949252" class="usa-link" aria-describedby="b19-medscimonit-31-e949252">19</a>].</p></section><section id="sec4"><h3 class="pmc_sec_title">Posterior Uveal Melanoma Staging – American Joint Committee on Cancer Classification</h3>
<p>The classification published by the American Joint Committee on Cancer (AJCC) includes 4 stages of posterior uveal melanoma (choroidal and ciliary body), from the least advanced (T1) to the most advanced (T4). Each stage is further classified into T category subclassification depending on the involvement of the ciliary body and extra-ocular spread or lack thereof [<a href="#b1-medscimonit-31-e949252" class="usa-link" aria-describedby="b1-medscimonit-31-e949252">1</a>]. Posterior uveal melanomas are most often diagnosed as T1 lesions, with T4 tumors being the rarest. Melanomas involving the ciliary body and showing extra-scleral extensions have a high risk of rapid metastasis. The AJCC classification of posterior uveal melanomas plays an essential role in clinical practice as a determinant of prognosis and melanoma staging (<a href="#t1-medscimonit-31-e949252" class="usa-link">Tables 1</a>–<a href="#t5-medscimonit-31-e949252" class="usa-link">5</a>).</p>
<section class="tw xbox font-sm" id="t1-medscimonit-31-e949252"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>The AJCC<a href="#tfn1-medscimonit-31-e949252" class="usa-link"><sup>*</sup></a> cancer staging system for posterior uveal melanoma (choroidal and ciliary body) in regard to size – T category (T1–T4).</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="box" rules="rows">
<thead><tr>
<th valign="middle" align="center" rowspan="1" colspan="1">Thickness (mm)</th>
<th valign="middle" align="center" rowspan="1" colspan="1"></th>
<th valign="middle" align="center" rowspan="1" colspan="1"></th>
<th valign="middle" align="center" rowspan="1" colspan="1"></th>
<th valign="middle" align="center" rowspan="1" colspan="1"></th>
<th valign="middle" align="center" rowspan="1" colspan="1"></th>
<th valign="middle" align="center" rowspan="1" colspan="1"></th>
<th valign="middle" align="center" rowspan="1" colspan="1"></th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">&gt;15.0</td>
<td valign="top" align="center" rowspan="1" colspan="1">4</td>
<td valign="top" align="center" rowspan="1" colspan="1">4</td>
<td valign="top" align="center" rowspan="1" colspan="1">4</td>
<td valign="top" align="center" rowspan="1" colspan="1">4</td>
<td valign="top" align="center" rowspan="1" colspan="1">4</td>
<td valign="top" align="center" rowspan="1" colspan="1">4</td>
<td valign="top" align="center" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">12.1–15.0</td>
<td valign="top" align="center" rowspan="1" colspan="1">3</td>
<td valign="top" align="center" rowspan="1" colspan="1">3</td>
<td valign="top" align="center" rowspan="1" colspan="1">3</td>
<td valign="top" align="center" rowspan="1" colspan="1">3</td>
<td valign="top" align="center" rowspan="1" colspan="1">3</td>
<td valign="top" align="center" rowspan="1" colspan="1">4</td>
<td valign="top" align="center" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">9.1–12.0</td>
<td valign="top" align="center" rowspan="1" colspan="1">3</td>
<td valign="top" align="center" rowspan="1" colspan="1">3</td>
<td valign="top" align="center" rowspan="1" colspan="1">3</td>
<td valign="top" align="center" rowspan="1" colspan="1">3</td>
<td valign="top" align="center" rowspan="1" colspan="1">3</td>
<td valign="top" align="center" rowspan="1" colspan="1">3</td>
<td valign="top" align="center" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">6.1–9.0</td>
<td valign="top" align="center" rowspan="1" colspan="1">2</td>
<td valign="top" align="center" rowspan="1" colspan="1">2</td>
<td valign="top" align="center" rowspan="1" colspan="1">2</td>
<td valign="top" align="center" rowspan="1" colspan="1">2</td>
<td valign="top" align="center" rowspan="1" colspan="1">3</td>
<td valign="top" align="center" rowspan="1" colspan="1">3</td>
<td valign="top" align="center" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">3.1–6.0</td>
<td valign="top" align="center" rowspan="1" colspan="1">1</td>
<td valign="top" align="center" rowspan="1" colspan="1">1</td>
<td valign="top" align="center" rowspan="1" colspan="1">1</td>
<td valign="top" align="center" rowspan="1" colspan="1">2</td>
<td valign="top" align="center" rowspan="1" colspan="1">2</td>
<td valign="top" align="center" rowspan="1" colspan="1">3</td>
<td valign="top" align="center" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">≤.0</td>
<td valign="top" align="center" rowspan="1" colspan="1">1</td>
<td valign="top" align="center" rowspan="1" colspan="1">1</td>
<td valign="top" align="center" rowspan="1" colspan="1">1</td>
<td valign="top" align="center" rowspan="1" colspan="1">1</td>
<td valign="top" align="center" rowspan="1" colspan="1">2</td>
<td valign="top" align="center" rowspan="1" colspan="1">2</td>
<td valign="top" align="center" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="center" rowspan="1" colspan="1">≤3.0</td>
<td valign="top" align="center" rowspan="1" colspan="1">3.1–6.0</td>
<td valign="top" align="center" rowspan="1" colspan="1">6.1–9.0</td>
<td valign="top" align="center" rowspan="1" colspan="1">9.1–12.0</td>
<td valign="top" align="center" rowspan="1" colspan="1">12.1–15.0</td>
<td valign="top" align="center" rowspan="1" colspan="1">15.1–18.0</td>
<td valign="top" align="center" rowspan="1" colspan="1">&gt;18.0</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td colspan="7" valign="top" align="left" rowspan="1">
<strong>Largest basal diameter (mm)</strong>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/t1-medscimonit-31-e949252/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tfn1-medscimonit-31-e949252">
<sup>*</sup><p class="display-inline">AJCC – American Joint Committee on Cancer.</p>
</div>
<div class="fn" id="tfn2-medscimonit-31-e949252"><p>Source: <em>Adapted from the AJCC Cancer Staging Manual, 8</em><em><sup>th</sup></em><em> ed. [<a href="#b1-medscimonit-31-e949252" class="usa-link" aria-describedby="b1-medscimonit-31-e949252">1</a>]</em>.</p></div>
</div></section><section class="tw xbox font-sm" id="t2-medscimonit-31-e949252"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>The AJCC<a href="#tfn3-medscimonit-31-e949252" class="usa-link"><sup>*</sup></a> cancer staging system for posterior uveal melanoma (choroidal and ciliary body) in regard to ciliary body involvement and extra-ocular extension – T category. subclassification.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="box" rules="rows">
<thead><tr>
<th valign="middle" align="center" rowspan="1" colspan="1">T category</th>
<th valign="middle" align="center" rowspan="1" colspan="1">T criteria</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">TX</td>
<td valign="top" align="left" rowspan="1" colspan="1">Primary tumor cannot be assessed</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T0</td>
<td valign="top" align="left" rowspan="1" colspan="1">No evidence of primary tumor</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T1</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor base ≤9 mm with thickness ≤6 mm<br>Tumor base 9.1–12 mm with thickness ≤3 mm</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T1a</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 1 without ciliary body involvement and extra-ocular extension</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T1b</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 1 with ciliary body involvement</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T1c</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 1 without ciliary body involvement but with extra-ocular extension ≤5 mm in largest diameter</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T1d</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 1 with ciliary body involvement and extra-ocular extension ≤5 mm in largest diameter</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T2</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor base ≤9 mm with thickness 6.1–9 mm<br>Tumor base 9.1–12 mm with thickness 3.1–9 mm<br>Tumor base 12.1–15 mm with thickness ≤6 mm<br>Tumor base 15.1–18 mm with thickness ≤3 mm</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T2a</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 2 without ciliary body involvement and extra-ocular extension</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T2b</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 2 with ciliary body involvement</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T2c</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 2 without ciliary body involvement but with extra-ocular extension ≤5 mm in largest diameter</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T2d</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 2 with ciliary body involvement and extra-ocular extension ≤5 mm in largest diameter</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T3</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor base 3.1–9 mm with thickness 9.1–12 mm<br>Tumor base 9.1–12 mm with thickness 9.1–15 mm<br>Tumor base 12.1–15 mm with thickness 6.1–15 mm<br>Tumor base 15.1–18 mm with thickness 3.1–12 mm</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T3a</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 3 without ciliary body involvement and extra-ocular extension</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T3b</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 3 with ciliary body involvement</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T3c</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 3 without ciliary body involvement but with extra-ocular extension ≤5 mm in largest diameter</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T3d</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 3 with ciliary body involvement and extra-ocular extension ≤5 mm in largest diameter</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T4</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor base 12.1–15 mm with thickness &gt;15 mm<br>Tumor base 15.1–18 mm with thickness &gt;12 mm<br>Tumor base &gt;18 mm with any thickness</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T4a</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 4 without ciliary body involvement and extra-ocular extension</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T4b</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 4 with ciliary body involvement</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T4c</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 4 without ciliary body involvement but with extra-ocular extension ≤5 mm in largest diameter</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T4d</td>
<td valign="top" align="left" rowspan="1" colspan="1">Tumor size category 4 with ciliary body involvement and extra-ocular extension ≤5 mm in largest diameter</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">T4e</td>
<td valign="top" align="left" rowspan="1" colspan="1">Any tumor size category with extra-ocular extension &gt;5 mm in largest diameter</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/t2-medscimonit-31-e949252/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tfn3-medscimonit-31-e949252">
<sup>*</sup><p class="display-inline">AJCC – American Joint Committee on Cancer.</p>
</div>
<div class="fn" id="tfn4-medscimonit-31-e949252"><p>Source: <em>Adapted from the AJCC Cancer Staging Manual, 8</em><em><sup>th</sup></em><em> ed. [<a href="#b1-medscimonit-31-e949252" class="usa-link" aria-describedby="b1-medscimonit-31-e949252">1</a>]</em>.</p></div>
</div></section><section class="tw xbox font-sm" id="t3-medscimonit-31-e949252"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>The AJCC<a href="#tfn5-medscimonit-31-e949252" class="usa-link"><sup>*</sup></a> cancer staging system for posterior uveal melanoma (choroidal and ciliary body) in regard to regional lymph nodes involvement and distant metastasis.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="box" rules="rows">
<thead><tr>
<th valign="top" align="center" rowspan="1" colspan="1"></th>
<th valign="top" align="center" rowspan="1" colspan="1">N criteria</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">NX</td>
<td valign="top" align="left" rowspan="1" colspan="1">Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">N0</td>
<td valign="top" align="left" rowspan="1" colspan="1">No regional lymph node involvement</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">N1</td>
<td valign="top" align="left" rowspan="1" colspan="1">Regional lymph node metastasis or discrete tumor deposits in the orbit</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">N1a</td>
<td valign="top" align="left" rowspan="1" colspan="1">Metastasis in one or more regional lymph node(s)</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">N1b</td>
<td valign="top" align="left" rowspan="1" colspan="1">No regional lymph nodes are positive, but there are discrete tumor deposits in the orbit that are not contiguous to the eye</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1">
<strong>M category</strong>
</td>
<td valign="top" align="center" rowspan="1" colspan="1">
<strong>M criteria</strong>
</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">M0</td>
<td valign="top" align="left" rowspan="1" colspan="1">No distant metastasis by clinical classification</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">M1</td>
<td valign="top" align="left" rowspan="1" colspan="1">Distant metastasis</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">M1a</td>
<td valign="top" align="left" rowspan="1" colspan="1">Largest diameter of the largest metastasis ≤3.0 cm</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">M1b</td>
<td valign="top" align="left" rowspan="1" colspan="1">Largest diameter of the largest metastasis 3.1–8.0 cm</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">M1c</td>
<td valign="top" align="left" rowspan="1" colspan="1">Largest diameter of the largest metastasis ≥8.1 cm</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/t3-medscimonit-31-e949252/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tfn5-medscimonit-31-e949252">
<sup>*</sup><p class="display-inline">AJCC – American Joint Committee on Cancer.</p>
</div>
<div class="fn" id="tfn6-medscimonit-31-e949252"><p>Source: <em>Adapted from the AJCC Cancer Staging Manual, 8</em><em><sup>th</sup></em><em> ed. [<a href="#b1-medscimonit-31-e949252" class="usa-link" aria-describedby="b1-medscimonit-31-e949252">1</a>]</em>.</p></div>
</div></section><section class="tw xbox font-sm" id="t4-medscimonit-31-e949252"><h4 class="obj_head">Table 4.</h4>
<div class="caption p"><p>The AJCC<a href="#tfn7-medscimonit-31-e949252" class="usa-link"><sup>*</sup></a> cancer staging system for posterior uveal melanoma (choroidal and ciliary body) – characteristics of stage group from I to IV.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="box" rules="rows">
<thead><tr>
<th valign="middle" align="center" rowspan="1" colspan="1">When T is…</th>
<th valign="middle" align="center" rowspan="1" colspan="1">When N is…</th>
<th valign="middle" align="center" rowspan="1" colspan="1">When M is…</th>
<th valign="middle" align="center" rowspan="1" colspan="1">Then the stage group is…</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">T1a</td>
<td valign="top" align="center" rowspan="1" colspan="1">N0</td>
<td valign="top" align="center" rowspan="1" colspan="1">M0</td>
<td valign="top" align="center" rowspan="1" colspan="1">I</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">T1b-d</td>
<td valign="top" align="center" rowspan="1" colspan="1">N0</td>
<td valign="top" align="center" rowspan="1" colspan="1">M0</td>
<td valign="top" align="center" rowspan="1" colspan="1">IIA</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">T2a</td>
<td valign="top" align="center" rowspan="1" colspan="1">N0</td>
<td valign="top" align="center" rowspan="1" colspan="1">M0</td>
<td valign="top" align="center" rowspan="1" colspan="1">IIA</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">T2b</td>
<td valign="top" align="center" rowspan="1" colspan="1">N0</td>
<td valign="top" align="center" rowspan="1" colspan="1">M0</td>
<td valign="top" align="center" rowspan="1" colspan="1">IIB</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">T3a</td>
<td valign="top" align="center" rowspan="1" colspan="1">N0</td>
<td valign="top" align="center" rowspan="1" colspan="1">M0</td>
<td valign="top" align="center" rowspan="1" colspan="1">IIB</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">T2c-d</td>
<td valign="top" align="center" rowspan="1" colspan="1">N0</td>
<td valign="top" align="center" rowspan="1" colspan="1">M0</td>
<td valign="top" align="center" rowspan="1" colspan="1">IIIA</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">T3b-c</td>
<td valign="top" align="center" rowspan="1" colspan="1">N0</td>
<td valign="top" align="center" rowspan="1" colspan="1">M0</td>
<td valign="top" align="center" rowspan="1" colspan="1">IIIA</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">T4a</td>
<td valign="top" align="center" rowspan="1" colspan="1">N0</td>
<td valign="top" align="center" rowspan="1" colspan="1">M0</td>
<td valign="top" align="center" rowspan="1" colspan="1">IIIA</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">T3d</td>
<td valign="top" align="center" rowspan="1" colspan="1">N0</td>
<td valign="top" align="center" rowspan="1" colspan="1">M0</td>
<td valign="top" align="center" rowspan="1" colspan="1">IIIB</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">T4b-c</td>
<td valign="top" align="center" rowspan="1" colspan="1">N0</td>
<td valign="top" align="center" rowspan="1" colspan="1">M0</td>
<td valign="top" align="center" rowspan="1" colspan="1">IIIB</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">T4d-e</td>
<td valign="top" align="center" rowspan="1" colspan="1">N0</td>
<td valign="top" align="center" rowspan="1" colspan="1">M0</td>
<td valign="top" align="center" rowspan="1" colspan="1">IIIC</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">Any T</td>
<td valign="top" align="center" rowspan="1" colspan="1">N1</td>
<td valign="top" align="center" rowspan="1" colspan="1">M0</td>
<td valign="top" align="center" rowspan="1" colspan="1">IV</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">Any T</td>
<td valign="top" align="center" rowspan="1" colspan="1">N1</td>
<td valign="top" align="center" rowspan="1" colspan="1">M1a-c</td>
<td valign="top" align="center" rowspan="1" colspan="1">IV</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/t4-medscimonit-31-e949252/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tfn7-medscimonit-31-e949252">
<sup>*</sup><p class="display-inline">AJCC – American Joint Committee on Cancer.</p>
</div>
<div class="fn" id="tfn8-medscimonit-31-e949252"><p>Source: <em>Adapted from the AJCC Cancer Staging Manual, 8</em><em><sup>th</sup></em><em> ed. [<a href="#b1-medscimonit-31-e949252" class="usa-link" aria-describedby="b1-medscimonit-31-e949252">1</a>]</em>.</p></div>
</div></section><section class="tw xbox font-sm" id="t5-medscimonit-31-e949252"><h4 class="obj_head">Table 5.</h4>
<div class="caption p"><p>The AJCC<a href="#tfn9-medscimonit-31-e949252" class="usa-link"><sup>*</sup></a> cancer staging system for posterior uveal melanoma (choroidal and ciliary body) in regard to histological grade.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="box" rules="rows">
<thead><tr>
<th valign="middle" align="center" rowspan="1" colspan="1">G category</th>
<th valign="middle" align="center" rowspan="1" colspan="1">G criteria</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">GX</td>
<td valign="top" align="left" rowspan="1" colspan="1">Grade cannot be assessed</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">G1</td>
<td valign="top" align="left" rowspan="1" colspan="1">Spindle cell melanoma (&gt;90% spindle cells)</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">G2</td>
<td valign="top" align="left" rowspan="1" colspan="1">Mixed-cell melanoma (&gt;10% epithelioid cells and &gt;90% spindle cells)</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">G3</td>
<td valign="top" align="left" rowspan="1" colspan="1">Epithelioid cell melanoma (&gt;90% epithelioid cells)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/t5-medscimonit-31-e949252/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tfn9-medscimonit-31-e949252">
<sup>*</sup><p class="display-inline">AJCC – American Joint Committee on Cancer.</p>
</div>
<div class="fn" id="tfn10-medscimonit-31-e949252"><p>Source: <em>Adapted from the AJCC Cancer Staging Manual, 8</em><em><sup>th</sup></em><em> ed. [<a href="#b1-medscimonit-31-e949252" class="usa-link" aria-describedby="b1-medscimonit-31-e949252">1</a>]</em>.</p></div>
</div></section></section><section id="sec5"><h3 class="pmc_sec_title">Posterior Uveal Melanoma – Prognostic Factors</h3>
<p>The prognosis of uveal melanoma is directly related to its cellular architecture and histological features. Epithelioid cell or mixed-cell melanomas, with high microvasculature density, extravascular matrix patterns such as closed loops, high mitotic index, and high proliferation index, are generally considered to have a poor prognosis [<a href="#b20-medscimonit-31-e949252" class="usa-link" aria-describedby="b20-medscimonit-31-e949252">20</a>]. The prognosis of spindle cell melanomas is generally better [<a href="#b16-medscimonit-31-e949252" class="usa-link" aria-describedby="b16-medscimonit-31-e949252">16</a>,<a href="#b21-medscimonit-31-e949252" class="usa-link" aria-describedby="b21-medscimonit-31-e949252">21</a>,<a href="#b22-medscimonit-31-e949252" class="usa-link" aria-describedby="b22-medscimonit-31-e949252">22</a>]. Another determinant of prognosis is the cytogenetic status of the tumor [<a href="#b23-medscimonit-31-e949252" class="usa-link" aria-describedby="b23-medscimonit-31-e949252">23</a>]. Melanomas harboring a mutation in the SF3B1 gene are more prone to metastatic spread, whereas the presence of EIF1AX mutation is associated with a relatively favorable prognosis [<a href="#b24-medscimonit-31-e949252" class="usa-link" aria-describedby="b24-medscimonit-31-e949252">24</a>]. In turn, the loss of the tumor suppressor gene BAP1 has been demonstrated to be associated with a rapid spread and markedly shorter survival [<a href="#b25-medscimonit-31-e949252" class="usa-link" aria-describedby="b25-medscimonit-31-e949252">25</a>]. Depending on the gene expression profile, uveal melanomas are classified into group I (low risk) and group II (high risk) lesions [<a href="#b26-medscimonit-31-e949252" class="usa-link" aria-describedby="b26-medscimonit-31-e949252">26</a>]. The co-existence of some chromosomal abnormalities, such as chromosome 1p deletion, monosomy 3, and chromosome 8q gain, is considered an unfavorable prognostic factor [<a href="#b27-medscimonit-31-e949252" class="usa-link" aria-describedby="b27-medscimonit-31-e949252">27</a>,<a href="#b28-medscimonit-31-e949252" class="usa-link" aria-describedby="b28-medscimonit-31-e949252">28</a>]. According to a large study, only 30% of patients with uveal melanomas had normal chromosomes 3 and 8, and the number of tumors with normal genetic status decreased significantly, with increasing AJCC stage and increasing tumor diameter as independent predictors [<a href="#b23-medscimonit-31-e949252" class="usa-link" aria-describedby="b23-medscimonit-31-e949252">23</a>]. AJCC stage III and abnormal copy numbers of chromosomes 3 and 8 were identified as significant predictors of poor prognosis. However, the prognostic value of the AJCC staging system decreased in tumors with normal genetic status.</p>
<p>Obviously, the lower the stage of the disease, the more favorable the prognosis. The risk of metastatic spread over 10 years increases with disease stage, from merely 15% for stage T1 to 63% for stage T4 [<a href="#b29-medscimonit-31-e949252" class="usa-link" aria-describedby="b29-medscimonit-31-e949252">29</a>]. The primary location of distant metastases is the liver (95%), followed by the lungs (28%), bones (18%), and skin (12%) [<a href="#b30-medscimonit-31-e949252" class="usa-link" aria-describedby="b30-medscimonit-31-e949252">30</a>]. The risk of metastatic spread is the lowest in the case of small melanomas up to 1 mm in thickness, which places particular emphasis on early detection of the disease.</p></section><section id="sec6"><h3 class="pmc_sec_title">Posterior Uveal Melanoma – Diagnostics</h3>
<p>The first steps in evaluating patients with suspected uveal melanoma include routine slit-lamp biomicroscopy, indirect fundus ophthalmoscopy, and pupil dilation. Careful inspection of the distant periphery of the fundus is of utmost importance, as lesions located there are easily overlooked. Uveal melanomas are more likely to develop in the eye periphery than at the posterior pole. If an intra-ocular tumor with potentially malignant characteristics is detected, routine biopsy and histopathological examination are not recommended, given the risk of cancer cell spread and retinal injury. Moreover, uveal melanoma biopsy is frequently associated with bleeding, both around the tumor and within the corpus vitreum [<a href="#b20-medscimonit-31-e949252" class="usa-link" aria-describedby="b20-medscimonit-31-e949252">20</a>]. Bleeding can hinder diagnostic imaging and prevent accurate placement of a radioactive plaque during brachytherapy. However, this does not mean that a uveal melanoma biopsy should not be performed. In line with the most recent approach, a biopsy can be performed while establishing a primary diagnosis; however, it aims to obtain material for further genetic testing rather than to confirm the diagnosis. Genetic tests are conducted to determine the patient’s specific risk of metastasis and to plan an individualized treatment strategy [<a href="#b31-medscimonit-31-e949252" class="usa-link" aria-describedby="b31-medscimonit-31-e949252">31</a>].</p>
<p>If a lesion is detected in the fundus, the diagnostic process needs to be expanded to confirm or exclude the possibility that the mass is malignant. Additional diagnostic procedures may include both non-invasive methods, such as ultrasonography (B-scan ultrasonography, color and power Doppler), OCT, and OCTA, and invasive procedures with the use of contrast agents, such as fluorescein angiography (FA) and indocyanine green angiography (IGA) [<a href="#b2-medscimonit-31-e949252" class="usa-link" aria-describedby="b2-medscimonit-31-e949252">2</a>,<a href="#b32-medscimonit-31-e949252" class="usa-link" aria-describedby="b32-medscimonit-31-e949252">32</a>]. Methods for visualizing vasculature and perfusion within tissues are particularly helpful in evaluating uveal melanoma, as this tumor has a dense vascular network. CT and MRI are rarely used to detect intra-ocular lesions. Their role is limited primarily to confirming an extra-ocular expansion and distinguishing contrast-enhancing uveal melanomas from non-enhancing hemorrhagic choroidal detachment and highly calcified choroidal osteoma [<a href="#b8-medscimonit-31-e949252" class="usa-link" aria-describedby="b8-medscimonit-31-e949252">8</a>]. The role of CT and MRI increases, however, if the fundus is not accessible for examination because of optic center opacity, such as corneal leukoma, presence of blood in the anterior chamber, mature cataract, or ciliary hemorrhage. Under such circumstances, ophthalmological examination using methods other than ultrasonography is impossible.</p>
<p>Considering all the diagnostic options mentioned above, other methods are needed to examine patients with suspected posterior uveal melanoma. Modern oncological diagnostics cannot be performed without PET/CT. Thus, the question arises as to whether this method could be helpful in the evaluation of posterior uveal melanoma and its role therein.</p></section></section><section id="sec7"><h2 class="pmc_sec_title">Positron Emission Tomography</h2>
<section id="sec8"><h3 class="pmc_sec_title">Positron Emission Tomography – The Idea and Technique of Examination</h3>
<p>Positron emission tomography (PET) is an imaging method from nuclear medicine, using radioactive substances that emit positrons (anti-electrons). During the examination, a small amount of a radiotracer, which is a radionuclide-labeled molecule with a short half-life that is rapidly metabolized in human tissues, is introduced into the human body.</p>
<p>Radiotracers are obtained by the fusion of 2 components: a ligand, which is a chemical that can accumulate within a given tissue or organ (eg, glucose, methionine, or choline), and a radionuclide (eg, <sup>18</sup>F or <sup>11</sup>C) that emits radiation at a detectable level. The ligand, which acts as a carrier for the radionuclide, is chosen based on the function of the given tissue. Radiotracers are also known as positron markers. Because of their short half-lives, radiotracers used in PET undergo rapid radioactive decay after reaching the target tissue or organ [<a href="#b33-medscimonit-31-e949252" class="usa-link" aria-describedby="b33-medscimonit-31-e949252">33</a>].</p>
<p>PET is based on annihilation, which refers to a reaction between a particle and its anti-particle, in the case of PET, positron, and electron, respectively. A positron is a positively charged (+1) particle with a charge and mass equal to that of a negatively charged electron (−1). During annihilation, the masses of both particles are converted into energy emitted as gamma quanta (photons). During PET, positrons emitted by a radiotracer undergo an annihilation reaction, colliding with electrons present within the tissue, which results in the formation of a pair of 511 keV gamma photons moving in opposite directions (at a 180° angle). The photons are detected using a concentric detector ring suitable for registering both coincidently released energy quanta and accurately locating their sources. The number of detector rings around the patient’s body can vary from 6 to 32. Each ring contains 4000–25 000 crystals. Images from the detectors are transmitted to a computer, where they are converted into 2D and 3D images. Therefore, PET is referred to as scanning. The radiation emitted during the examination is registered by a reader, which can estimate the metabolic activity of cells within the human body based on the rate of radioactive decay [<a href="#b33-medscimonit-31-e949252" class="usa-link" aria-describedby="b33-medscimonit-31-e949252">33</a>,<a href="#b34-medscimonit-31-e949252" class="usa-link" aria-describedby="b34-medscimonit-31-e949252">34</a>]. Because the examination involves radionuclides with short half-lives, most of the radiation is generated during the examination, thereby limiting the risk of radiation tissue injury. The sources of positrons are radioactive substances, such as carbon-11 (<sup>11</sup>C), gallium-68 (<sup>68</sup>Ga), fluorine-18 (<sup>18</sup>F), nitrogen-13 (<sup>13</sup>N), oxygen-15 (<sup>15</sup>O), and technetium-99 (<sup>99</sup>Tc). The ultrashort or short half-life of radiotracer isotopes is a strength of the examination, as it guarantees patient safety, but also a weakness, as the cyclotron producing the isotopes must be located in close proximity to a tomography examination room to facilitate fast delivery of the isotope when its activity is high. The half-life of the most commonly used isotope, <sup>18</sup>F, is 110 min, whereas the half-life of <sup>11</sup>C is 20 min [<a href="#b35-medscimonit-31-e949252" class="usa-link" aria-describedby="b35-medscimonit-31-e949252">35</a>]. Currently, the most popular radiotracer, most commonly used during PET, is fluorodeoxyglucose (FDG), which is a glucose analog labeled with fluorine-18 isotope, <sup>18</sup>F. Thus, PET allows visualization of the distribution and metabolism of FDG as a marker of glucose metabolism in the human body. FDG absorbed by cells is transformed into <sup>18</sup>F-deoxyglucose-6-phosphate in a process catalyzed by hexokinase. This newly formed compound does not undergo further metabolic processes and it cannot be released from the cells, a phenomenon referred to as a metabolic trap. Thus, <sup>18</sup>F-deoxyglucose-6-phosphate accumulates extensively in all the glucose-metabolizing organs. Glucose is the primary source of energy in the human body. In addition to the heart and brain, other areas of extensive glucose metabolism in the human body include inflammatory foci and malignant lesions. It is estimated that up to 90% of early-stage neoplasms can be detected using PET [<a href="#b36-medscimonit-31-e949252" class="usa-link" aria-describedby="b36-medscimonit-31-e949252">36</a>]. In addition to glucose metabolism, PET radiotracers can be used to evaluate other metabolic pathways that are disrupted in cancer cells. Considering the heterogeneity of human tissues in terms of their metabolic profiles, the evaluation of neoplastic lesions during PET can involve many radiotracers other than FDG. The most commonly used FDG alternatives include <sup>68</sup>Ga-PSMA (prostate-specific membrane antigen), <sup>11</sup>C-methionine, choline, and acetate labeled with <sup>11</sup>C and <sup>18</sup>F [<a href="#b34-medscimonit-31-e949252" class="usa-link" aria-describedby="b34-medscimonit-31-e949252">34</a>].</p></section><section id="sec9"><h3 class="pmc_sec_title">Positron Emission Tomography – Technology with Computed Tomography</h3>
<p>A recent breakthrough has been the introduction of hybrid total-body PET scanners combining PET technology with multi-slice spiral computed tomography or magnetic resonance imaging (PET/CT and PET/MRI systems, respectively). These hybrid scanners can visualize the anatomy of examined tissues and provide functional data on the site of PET radiotracer accumulation. The first PET/CT scanner was developed in 1998 and has become widely available in healthcare units since 2001.</p>
<p>Polyethylene terephthalate/CT is performed as follows: Approximately 1 hour before the examination, a radiotracer, for example, <sup>18</sup>F-FDG, is administered to the patient intravenously. During the first stage of PET, a short (9-second) whole-body scan, the so-called topogram, is obtained to verify correct patient placement. Computed tomography (CT) is performed to obtain a radiographic scan of the body, constituting a reference map for PET images. Finally, PET/CT begins, during which the detectors circle the long axis of the patient and proceed alongside the body. Scanning of the human body lasts approximately 20 minutes and consists of 6 or 7 stages of 3 minutes each. The number of stages depends on a patient body height. After completion of scanning, data from the detectors are transmitted to a computer and analyzed.</p>
<p>First, a qualitative analysis is conducted to verify whether a lesion visible on PET/CT accumulated the radiotracer. Quantitative analysis is then performed; digital images obtained during the body scan accurately depict the actual concentration of the tracer in a given organ, but not with 100% precision. In clinical practice, the quantitative kinetics of PET radiotracers are determined based on the standardized uptake value (SUV), defined as the ratio of tracer concentration within the tissue of interest (in MBq/ml) to the mean concentration of the tracer across the body (ie, administered activity per body weight [MBq/body weight in kg]) [<a href="#b37-medscimonit-31-e949252" class="usa-link" aria-describedby="b37-medscimonit-31-e949252">37</a>]. The SUV is calculated using the following formula:</p>
<table class="disp-formula p" id="fd1-medscimonit-31-e949252"><tr><td class="formula"><math id="m1" display="block" overflow="linebreak"><mrow><mtable><mtr><mtd><munder accentunder="true"><mrow><mtext>tracer uptake </mtext><mo stretchy="false">(</mo><mtext>in MBq</mtext><mo>/</mo><mtext>ml</mtext><mo stretchy="false">)</mo><mo>×</mo><mn>1000</mn></mrow><mo stretchy="true">_</mo></munder></mtd></mtr><mtr><mtd><mtext>SUV</mtext><mo>=</mo><mtext>administered activity </mtext><mo stretchy="false">(</mo><mtext>MBq</mtext><mo stretchy="false">)</mo><mo>/</mo><mtext>patients</mtext><mo>’</mo><mtext>s weight </mtext><mo stretchy="false">(</mo><mtext>kg</mtext><mo stretchy="false">)</mo></mtd></mtr></mtable></mrow></math></td></tr></table>
<p>SUV values greater than 2.5–3 correspond to a malignant character of the lesion, although no cut-off value exists to accurately distinguish neoplasms from normal tissues. Interpretation of results also depends on the SUV, showing the metabolic activity of normal tissues, which varies from organ to organ. The heart and brain have high metabolic rates, whereas metabolism within the lungs and bones is relatively low. Hence, the SUVs of normal tissues differ. For instance, SUV values for FDG vary from 0.7 for normal lung tissue, 1.0 for bone marrow, 0.5 for breasts, 2.5 for the liver, and 5.0 for the brain [<a href="#b37-medscimonit-31-e949252" class="usa-link" aria-describedby="b37-medscimonit-31-e949252">37</a>]. During the final interpretation of PET results for a suspected lesion, the background uptake of the tracer (ie, the uptake by the adjacent normal tissue) should also be considered. Background uptake is expressed as the tumor-to-background ratio (TBR), defined as the ratio of the SUVmax of the lesion to the SUVmean of healthy tissues. SUV and TBR values are more critical during the monitoring of treatment outcomes than are isolated parameters.</p>
<p>Posterior uveal melanoma is suitable for PET/CT evaluation, similar to other highly aggressive malignant tumors, and is characterized by a higher glucose consumption and, consequently, a higher <sup>18</sup>F-FDG uptake, which is reflected by high SUVmax values [<a href="#b38-medscimonit-31-e949252" class="usa-link" aria-describedby="b38-medscimonit-31-e949252">38</a>,<a href="#b39-medscimonit-31-e949252" class="usa-link" aria-describedby="b39-medscimonit-31-e949252">39</a>]. SUVmax values &gt;2.5 are generally considered a marker of high metabolic activity of the tumor, but some studies have used 2 cut-off values, 2.5 and/or 4.0.</p>
<p>Compared with the SUV, the metabolic rate of glucose (MRglu, in milliliters per minute per 100 g) is a better measure of glucose consumption by a tumor. MRglu is an outcome of the <sup>18</sup>F-FDG clearance rate and blood glucose concentration. Thus, MRglu is used during the qualitative analysis of the PET images, whereas SUV is considered a semiquantitative parameter. SUVs are used more frequently in clinical practice because they are easier to calculate. However, the SUV is only a surrogate for qualitative parameters, as it is an estimate of glucose consumption by a tumor. More accurate results can be obtained through a qualitative analysis based on MRglu, which measures actual glucose consumption. However, given that the calculation of MRglu is more complex and time-consuming than SUVmax and SUVmean, this parameter is not routinely used when interpreting PET/CT results [<a href="#b40-medscimonit-31-e949252" class="usa-link" aria-describedby="b40-medscimonit-31-e949252">40</a>].</p></section></section><section id="sec10"><h2 class="pmc_sec_title">Role of PET/CT in the Detection of Posterior Uveal Melanoma</h2>
<section id="sec11"><h3 class="pmc_sec_title">Relationship Between PET/CT Imaging of Uveal Melanoma and Tumor Size</h3>
<p>The first reports on the application of PET/CT for detecting uveal melanomas date back to the first years when this technique was utilized. Reddy et al [<a href="#b41-medscimonit-31-e949252" class="usa-link" aria-describedby="b41-medscimonit-31-e949252">41</a>] examined 50 untreated choroidal melanomas (AJCC stages T1 to T3) and found that 14 of them – 8 (33%) medium (T2) tumors and 6 (75%) large (T3) tumors – had uptake and metabolism of a tracer, <sup>18</sup>F-FDG (SUV &gt;2.5). PET/CT did not reveal any small uveal melanomas. The smallest detectable tumor had a base diameter of 3×5.9 mm and a thickness of 2.9 mm. The mean resolution of PET/CT images is 3–4 mm; hence, smaller lesions can easily be overlooked. The smallest uveal melanoma detected by PET/CT in a study conducted by Spraul et al [<a href="#b42-medscimonit-31-e949252" class="usa-link" aria-describedby="b42-medscimonit-31-e949252">42</a>] was 3×7 mm, confirming that PET/CT is not superior to routine ophthalmological evaluation for detection of smaller tumors. Finger et al [<a href="#b38-medscimonit-31-e949252" class="usa-link" aria-describedby="b38-medscimonit-31-e949252">38</a>] found an increased SUV (&gt;2.5) in 11 of 14 choroidal melanomas (T2 and T3). The higher detection rate of melanomas in the study conducted by these authors was associated with the lack of small tumors in their material. Interestingly, the SUVmax for tumors diagnosed more than 10 years before PET/CT exceeded 4.0. Tumors with the highest SUVmax values were primarily composed of epithelioid cells, contained large-diameter (&gt;150 μm) blood vessels, were more often located anteriorly to the equator of the eye, and had a large base. The maximum SUVmax for the largest tumors was 9. McCannelet et al [<a href="#b43-medscimonit-31-e949252" class="usa-link" aria-describedby="b43-medscimonit-31-e949252">43</a>] observed SUV &gt;2.5 solely in larger melanomas with a mean diameter of 14.6 mm and a mean thickness of 7.4 mm. Metabolically inactive melanomas (SUV &lt;2.5) had a mean diameter of 10 mm and a mean thickness of 5.0 mm. Matsuo et al [<a href="#b22-medscimonit-31-e949252" class="usa-link" aria-describedby="b22-medscimonit-31-e949252">22</a>] also found a positive correlation between SUVmax and tumor diameter. According to these authors, all PET/CT-detectable tumors were dome-shaped and clearly extruded into the vitreous cavity. Lesions that were not detected on PET/CT were flat, diffuse, and/or formed small mushroom-like protrusions. Singh et al [<a href="#b44-medscimonit-31-e949252" class="usa-link" aria-describedby="b44-medscimonit-31-e949252">44</a>] analyzed the relationship between the detectability of uveal melanomas on PET/CT and tumor size. The analysis included tumors with no evidence of distant metastasis. The melanoma detection rate on PET was 60%, and it was correlated with tumor size. Detectable tumors had diameters of at least 13 mm, thickness of 4.5 mm, 565 mm<sup>3</sup> volume, and SUVmax values of 3.5–8.6. Their study confirmed that small uveal melanomas are not visible on PET/CT and would remain undetected if this method was used as the only diagnostic option. They postulated that the lack of melanoma detection on PET/CT might be associated not only with the small diameter of the tumor but also with the effect of other factors, such as concomitant inflammation, necrosis or lack thereof, intratumoral hemorrhage, and tumor vascularization on glucose metabolism [<a href="#b40-medscimonit-31-e949252" class="usa-link" aria-describedby="b40-medscimonit-31-e949252">40</a>,<a href="#b44-medscimonit-31-e949252" class="usa-link" aria-describedby="b44-medscimonit-31-e949252">44</a>,<a href="#b45-medscimonit-31-e949252" class="usa-link" aria-describedby="b45-medscimonit-31-e949252">45</a>]. According to Calcagni et al [<a href="#b40-medscimonit-31-e949252" class="usa-link" aria-describedby="b40-medscimonit-31-e949252">40</a>], the PET/CT detectability of medium and large melanomas qualified for surgical treatment reached 88.5%. Surgical treatment is dedicated primarily to large lesions, and the results of the study mentioned above confirm that the larger the examined tumor, the more likely it is to be visualized on PET/CT. In line with these findings, Leško et al [<a href="#b46-medscimonit-31-e949252" class="usa-link" aria-describedby="b46-medscimonit-31-e949252">46</a>] found hypermetabolism on PET/CT scans only in tumors with volumes greater than 565 mm<sup>3</sup>.</p></section><section id="sec12"><h3 class="pmc_sec_title">Relationship Between PET/CT Imaging of Uveal Melanoma and Histological Characteristics</h3>
<p>Analysis of the correlation between FDG uptake on PET/CT and the histopathological characteristics of posterior uveal melanoma is possible only in tumors treated by resection or enucleation. A study analyzing glucose consumption, a parameter that is considerably elevated in malignant and aggressive tumors, demonstrated that epithelioid cell melanomas presented with significantly higher MRglu values (mean 27.8 ml/min/100 g) than spindle cell melanomas (mean 13.8 ml/min/100 g). MRglu values for mixed tumors were moderate, with a mean value of 19.73 ml/min/100 g [<a href="#b40-medscimonit-31-e949252" class="usa-link" aria-describedby="b40-medscimonit-31-e949252">40</a>]. These findings are in agreement with the observation that epithelioid and mixed-cell melanomas exhibit aggressive phenotypes. Although the same study did not show significant cellular structure-related differences in SUVmax values, more aggressive melanomas (epithelioid and mixed-cell tumors) had higher values of this parameter (4.6 and 4.1, respectively) than spindle cell melanomas (2.9) [<a href="#b40-medscimonit-31-e949252" class="usa-link" aria-describedby="b40-medscimonit-31-e949252">40</a>]. In a multivariate analysis analyzing a link between histopathological features corresponding to the aggressive phenotype of uveal melanoma (tumor size, mitotic index, proliferative index, density of microvasculature, epithelioid or mixed cells, Ki67) and qualitative (MRglu) and semiquantitative (SUV) PET/CT indices, the cut-off values that most accurately identified high-risk tumors were SUVmax &gt;4.16 and MRglu &gt;21.96 ml/min/100 g. According to Calcagni et al [<a href="#b40-medscimonit-31-e949252" class="usa-link" aria-describedby="b40-medscimonit-31-e949252">40</a>], the application of these 2 parameters for the identification of high-risk choroidal melanomas may result in the development of a reliable diagnostic test with high sensitivity (few false negatives) and high positive predictive value (few false positives). Using the cut-off values presented above, the authors obtained 71% sensitivity and 92% positive predictive value for identifying high-risk melanomas.</p></section><section id="sec13"><h3 class="pmc_sec_title">Relationship Between PET/CT Imaging of Uveal Melanoma and Chromosome 3 Loss</h3>
<p>Loss of chromosome 3 is a risk factor for uveal melanoma development and it is usually associated with a more aggressive tumor phenotype. McCannel et al [<a href="#b43-medscimonit-31-e949252" class="usa-link" aria-describedby="b43-medscimonit-31-e949252">43</a>] found a significant association between monosomy 3 and enhanced glucose metabolism within the tumor, which manifested as higher SUVmax values. The results showed a sensitivity of 54% and a specificity of 100%. Papastefanou et al [<a href="#b27-medscimonit-31-e949252" class="usa-link" aria-describedby="b27-medscimonit-31-e949252">27</a>] also showed a positive correlation between the metabolic activity of uveal melanoma, monosomy 3, and other prognostic factors, including larger tumor size and TNM prognosis. Up to 92% of the examined melanomas had an SUVmax of &gt;2.5, and in 67%, the SUVmax exceeded 4.0. However, the material analyzed by these authors did not include small melanomas and large tumors constituted up to 84% of the sample. Up to 94% of melanomas with monosomy 3 had an SUVmax &gt;2.5, and up to 80% had an SUVmax greater than 4.0. The authors of that study did not observe a considerable increase in SUVmax in uveal melanomas with chromosome 8q gain, which is another anomaly considered an unfavorable prognostic factor. However, melanomas with monosomy 3 coexisting with chromosome 8q gain had higher SUVmax values than those with monosomy 3 as an isolated chromosomal abnormality. The same study found no significant association between an increase in SUVmax and the predominance of epithelioid cells in tumor architecture, necrosis, inflammatory infiltration, or hemorrhage. These findings are in contrast to the results published by other authors, who observed higher SUVmax values in epithelioid and mixed-cell tumors [<a href="#b38-medscimonit-31-e949252" class="usa-link" aria-describedby="b38-medscimonit-31-e949252">38</a>,<a href="#b47-medscimonit-31-e949252" class="usa-link" aria-describedby="b47-medscimonit-31-e949252">47</a>] and in tumors with concomitant necrosis and local inflammation [<a href="#b45-medscimonit-31-e949252" class="usa-link" aria-describedby="b45-medscimonit-31-e949252">45</a>,<a href="#b47-medscimonit-31-e949252" class="usa-link" aria-describedby="b47-medscimonit-31-e949252">47</a>]. According to Yamada et al [<a href="#b39-medscimonit-31-e949252" class="usa-link" aria-describedby="b39-medscimonit-31-e949252">39</a>], increased FDG uptake by uveal melanomas may be associated with a high proliferation index and high viability of tumor cells.</p></section></section><section id="sec14"><h2 class="pmc_sec_title">Role of PET/CT Imaging in Distinguishing Between Posterior Uveal Melanomas, Benign Lesions and Other Primary or Metastatic Intra-Ocular Malignancies</h2>
<section id="sec15"><h3 class="pmc_sec_title">Choroidal Nevus</h3>
<p>Distinguishing between uveal melanoma and choroidal nevus is one of the greatest challenges in differential diagnosis. Choroidal nevus is a benign intra-ocular mass that is typically found in Whites, and according to the Blue Mountains Eye Study [<a href="#b48-medscimonit-31-e949252" class="usa-link" aria-describedby="b48-medscimonit-31-e949252">48</a>], it has a prevalence of 7%. A nevus usually presents as a well-demarcated, flat, round, or longitudinal area of increased choroidal pigmentation with a dark color. However, amelanotic nevi have also been reported previously. In 91% of cases, choroidal nevi are located posterior to the equator and have a similar frequency, regardless of the eye quadrant [<a href="#b49-medscimonit-31-e949252" class="usa-link" aria-describedby="b49-medscimonit-31-e949252">49</a>]. The mean diameter of the choroidal nevus is estimated to be 5 mm, with a mean thickness of 1–1.5 mm. Frequently, the nevus is surrounded by drusen and an altered retinal pigment epithelium [<a href="#b50-medscimonit-31-e949252" class="usa-link" aria-describedby="b50-medscimonit-31-e949252">50</a>].</p>
<p>Each identified choroidal nevus should be regularly monitored for potential malignant transformation. Features that may be associated with an increased risk of transformation to choroidal melanoma include thickness &gt;2.0 mm, diameter &gt;5 mm, accumulation of an orange pigment and/or subretinal fluid, &lt;3.0 mm distance from the fovea or optic disc, ultrasonographic acoustic hollowness, floaters, flashes, and blurred vision [<a href="#b50-medscimonit-31-e949252" class="usa-link" aria-describedby="b50-medscimonit-31-e949252">50</a>,<a href="#b51-medscimonit-31-e949252" class="usa-link" aria-describedby="b51-medscimonit-31-e949252">51</a>]. The presence of at least 3 of these features is associated with a 50% risk of malignant transformation within the next 5 years [<a href="#b52-medscimonit-31-e949252" class="usa-link" aria-describedby="b52-medscimonit-31-e949252">52</a>].</p>
<p>Although observing skin nevi for potential malignant transformation is relatively simple, follow-up of choroidal nevi is complicated. This has stimulated research on new alternative techniques to specialist ophthalmological examinations (FA, IGA, OCT, and OCTA) that could replace the direct histological analysis of the lesion, which is the only accurate diagnostic method currently available. Choroidal nevi typically need to be differentiated from small, thinner melanomas. Mathematical analyses of tumor doubling and the results of The Collaborative Ocular Melanoma Study (COMS) suggest that metastatic spread of choroidal melanoma can occur even at the very early stages when a small tumor is typically described as a “suspicious choroidal nevus” [<a href="#b53-medscimonit-31-e949252" class="usa-link" aria-describedby="b53-medscimonit-31-e949252">53</a>,<a href="#b54-medscimonit-31-e949252" class="usa-link" aria-describedby="b54-medscimonit-31-e949252">54</a>]. Theoretically, differential diagnosis can be facilitated by analyzing the metabolic activity within the lesion, assuming that malignant tumors are more metabolically active than nevi. However, small choroidal melanomas cannot be detected using PET/CT. Detecting choroidal nevi can also be challenging, given their thinness. The group of patients examined by Spraul et al [<a href="#b42-medscimonit-31-e949252" class="usa-link" aria-describedby="b42-medscimonit-31-e949252">42</a>] included 6 with choroidal or ciliary body nevi, and none of these lesions were detected on PET/CT. In view of these findings, the role of PET/CT in distinguishing choroidal melanomas from choroidal nevi remains limited [<a href="#b2-medscimonit-31-e949252" class="usa-link" aria-describedby="b2-medscimonit-31-e949252">2</a>].</p></section><section id="sec16"><h3 class="pmc_sec_title">Benign Intra-Ocular Lesions</h3>
<p>Benign intra-ocular lesions such as hemangiomas of the choroid and extrafoveal choroidal neovascularization, which may need to be differentiated from choroidal melanoma, also yield negative results on PET/CT [<a href="#b42-medscimonit-31-e949252" class="usa-link" aria-describedby="b42-medscimonit-31-e949252">42</a>]. This suggests that PET/CT is not suitable for evaluating metabolically inactive benign lesions. The lack of metabolic activity on PET/CT could mean that the lesion is not malignant. Unfortunately, under this assumption, small uveal melanomas that are undetectable on PET/CT can be misdiagnosed as benign. However, PET/CT is not sufficiently sensitive to detect such lesions.</p></section><section id="sec17"><h3 class="pmc_sec_title">Other Primary or Metastatic Intra-Ocular Malignancies</h3>
<p>PET/CT can be helpful in the differential diagnosis of intra-ocular tumors, given that some malignancies, including retinoblastoma and low-grade mucosa-associated lymphoid tissue lymphoma, have very low FDG uptake [<a href="#b3-medscimonit-31-e949252" class="usa-link" aria-describedby="b3-medscimonit-31-e949252">3</a>], which differentiates them from uveal melanomas. However, ophthalmic lymphoma derives from the orbital tissues, eyelids, and cornea instead of being a primary intra-ocular tumor, and retinoblastoma occurs primarily in children; therefore, these tumors are rarely considered as differential diagnoses during the evaluation of suspected uveal melanoma.</p>
<p>As a richly vascularized tissue, the choroid is often a site of metastatic spread for malignancies located in other organs, such as the breast, lung, or prostate. Although both ocular metastases and primary tumors can be detected using FDG-PET/CT, this method is not superior to other methods for differentiating between intra-ocular metastases and primary uveal melanoma. Available evidence suggests that these 2 tumor types do not differ in their metabolic activity and thus cannot be differentiated on PET/CT [<a href="#b4-medscimonit-31-e949252" class="usa-link" aria-describedby="b4-medscimonit-31-e949252">4</a>].</p></section></section><section id="sec18"><h2 class="pmc_sec_title">Role of PET/CT in Staging of Metastatic Uveal Melanoma</h2>
<section id="sec19"><h3 class="pmc_sec_title">Metastatic Uveal Melanoma</h3>
<p>Neoplasm staging is essential for planning therapeutic strategies. Despite treatment, approximately 50% of patients with uveal melanoma eventually develop distant metastases [<a href="#b6-medscimonit-31-e949252" class="usa-link" aria-describedby="b6-medscimonit-31-e949252">6</a>,<a href="#b55-medscimonit-31-e949252" class="usa-link" aria-describedby="b55-medscimonit-31-e949252">55</a>]. The route of spread is associated with the eye anatomy. Since the eye does not have lymphatic vessels (present solely in the conjunctiva), uveal melanoma spreads through the blood, and its distant metastases are found primarily in the liver [<a href="#b14-medscimonit-31-e949252" class="usa-link" aria-describedby="b14-medscimonit-31-e949252">14</a>]. Other markedly less frequent locations of uveal melanoma metastases include the lungs, skin, abdominal cavity, pelvis, and brain [<a href="#b18-medscimonit-31-e949252" class="usa-link" aria-describedby="b18-medscimonit-31-e949252">18</a>]. Treatment options for metastatic uveal melanoma are quite limited. Whenever possible, the primary lesion is surgically removed, which, in some cases, requires enucleation. Surgery is combined with systemic chemotherapy. Other treatment options include chemoembolization or radioembolization and targeted hepatic chemotherapy [<a href="#b14-medscimonit-31-e949252" class="usa-link" aria-describedby="b14-medscimonit-31-e949252">14</a>]. Some patients with metastatic uveal melanoma can also qualify for immunotherapy with small-molecule kinase inhibitors and immune modulators [<a href="#b56-medscimonit-31-e949252" class="usa-link" aria-describedby="b56-medscimonit-31-e949252">56</a>].</p>
<p>Although evidence of metastatic spread is found in less than 1% of patients at the time of uveal melanoma diagnosis, the risk of metastasis increases substantially with disease duration. PET/CT can also be used to monitor patients with uveal melanoma for potential metastatic spread [<a href="#b46-medscimonit-31-e949252" class="usa-link" aria-describedby="b46-medscimonit-31-e949252">46</a>]. According to Freton et al [<a href="#b57-medscimonit-31-e949252" class="usa-link" aria-describedby="b57-medscimonit-31-e949252">57</a>], PET/CT detected metastases in 4% of the patients with newly diagnosed melanoma. It must be stressed that even if primary uveal melanoma can be controlled through local treatment, the patient may still die because of subclinical micrometastases present at the time of the initial diagnosis. In line with the UK National Guidelines for managing uveal melanoma, tumor staging is an essential component [<a href="#b58-medscimonit-31-e949252" class="usa-link" aria-describedby="b58-medscimonit-31-e949252">58</a>], as accurate determination of the disease stage can optimize further therapeutic approaches.</p></section><section id="sec20"><h3 class="pmc_sec_title">Application of PET/CT to Evaluation of Liver Metastases from Uveal Melanoma</h3>
<p>As the liver is the primary location of distant metastases in uveal melanoma, most published studies have dealt with the application of PET/CT to evaluate this organ. Liver lesions were interpreted as metastases if their SUVmax on PET/CT was higher than that of the adjacent tissues. The SUVmax for normal liver tissues did not exceed 2.5. The metabolic activity of a lesion could also be estimated based on its TBR, with higher values of this parameter corresponding to more metabolically active and, hence, more aggressive masses. Del Carpio et al [<a href="#b59-medscimonit-31-e949252" class="usa-link" aria-describedby="b59-medscimonit-31-e949252">59</a>] estimated the mean SUVmax for the liver metastases of uveal melanoma is 8.5 (range, 2.6–42.2). Lesions with low SUVmax values, similar to normal liver uptake, and TBR &lt;1.1 constituted 19.6% of all identified metastatic tumors. The largest of the metastases with the lowest metastatic activity (TBR &lt;1.1) had a mean diameter of 10.5 mm (range, 8–50 mm), whereas the mean diameter of metabolically active (TBR &gt;1.1) metastatic lesions was 24 mm (range, 10–178). All tumors with diameters &gt;50 mm were metabolically active, whereas all metastases with diameters &lt;10 mm were iso-metabolic [<a href="#b59-medscimonit-31-e949252" class="usa-link" aria-describedby="b59-medscimonit-31-e949252">59</a>].</p>
<p>Although PET/CT is not routinely used to detect uveal melanoma metastases to the liver, it has become an important examination in patients with normal CT results and normal liver enzyme levels [<a href="#b60-medscimonit-31-e949252" class="usa-link" aria-describedby="b60-medscimonit-31-e949252">60</a>]. Several studies have demonstrated that liver function tests have poor sensitivity for detecting liver metastases [<a href="#b61-medscimonit-31-e949252" class="usa-link" aria-describedby="b61-medscimonit-31-e949252">61</a>]. In turn, the results of the COMS group study suggest that liver function tests provide high specificity and predictive values, but low sensitivity in identifying choroidal melanoma metastases to the liver [<a href="#b54-medscimonit-31-e949252" class="usa-link" aria-describedby="b54-medscimonit-31-e949252">54</a>]. PET/CT also plays an essential role in the detection of metastatic uveal melanoma in patients with contraindications to MRI. Some evidence suggests that PET/CT can detect liver metastases that remain invisible on abdominal ultrasound [<a href="#b56-medscimonit-31-e949252" class="usa-link" aria-describedby="b56-medscimonit-31-e949252">56</a>,<a href="#b57-medscimonit-31-e949252" class="usa-link" aria-describedby="b57-medscimonit-31-e949252">57</a>]. Nevertheless, ultrasonography is an excellent tool for detecting benign liver lesions, which, unlike malignant masses, have no metabolic activity and cannot be visualized using PET/CT. Cohen et al [<a href="#b56-medscimonit-31-e949252" class="usa-link" aria-describedby="b56-medscimonit-31-e949252">56</a>] examined 108 uveal melanomas for potential liver spread by using PET/CT and ultrasonography. Although malignant lesions could be visualized effectively on PET/CT, benign liver lesions in 18% of patients could be detected solely on ultrasound, with PET/CT yielding a negative result. These findings confirm that PET/CT and ultrasound are complementary methods, and should be used together in the staging of uveal melanoma.</p>
<p>In some studies, PET/CT yielded 100% sensitivity and 100% specificity in detecting uveal melanoma metastases to the liver [<a href="#b61-medscimonit-31-e949252" class="usa-link" aria-describedby="b61-medscimonit-31-e949252">61</a>,<a href="#b62-medscimonit-31-e949252" class="usa-link" aria-describedby="b62-medscimonit-31-e949252">62</a>]. However, according to Strobel et al [<a href="#b63-medscimonit-31-e949252" class="usa-link" aria-describedby="b63-medscimonit-31-e949252">63</a>], the sensitivity of PET/CT in detecting liver metastases was only 59%. Kurle et al [<a href="#b61-medscimonit-31-e949252" class="usa-link" aria-describedby="b61-medscimonit-31-e949252">61</a>] demonstrated that the sensitivity of liver function tests for detecting liver metastases was only 12.5%, which is much lower than the 100% sensitivity of PET/CT. Francken et al [<a href="#b64-medscimonit-31-e949252" class="usa-link" aria-describedby="b64-medscimonit-31-e949252">64</a>] highlighted the role of FDG-PET/CT in the detection of isolated and potentially resectable liver metastases, as this method provided 100% sensitivity and 67% specificity, along with positive and negative predictive values of 88% and 100%, respectively. According to Servious et al [<a href="#b65-medscimonit-31-e949252" class="usa-link" aria-describedby="b65-medscimonit-31-e949252">65</a>], the sensitivities of MRI and PET/CT for staging liver metastases were 67% and 41%, respectively, with positive predictive values of 95% and 100%, respectively.</p></section><section id="sec21"><h3 class="pmc_sec_title">Application of PET/CT to Evaluation of Other Metastases From Uveal Melanoma</h3>
<p>Finger et al [<a href="#b66-medscimonit-31-e949252" class="usa-link" aria-describedby="b66-medscimonit-31-e949252">66</a>] confirmed that PET/CT is useful in detecting metastases not only to the liver, but also to the bones and lymphatic nodes. Additionally, PET/CT detected benign lesions in the bones, lungs, lymph nodes, large intestine, and rectum in 13.4% of patients with choroidal melanoma. However, the study group also included 5.7% of patients in whom the presence of suspected malignant lesions on PET/CT scans was not confirmed on histopathological examination [<a href="#b66-medscimonit-31-e949252" class="usa-link" aria-describedby="b66-medscimonit-31-e949252">66</a>]. In a study by Kurli et al [<a href="#b61-medscimonit-31-e949252" class="usa-link" aria-describedby="b61-medscimonit-31-e949252">61</a>], concomitant benign lesions in the bones and lymph nodes (inflammation and old fractures) were detected by PET/CT in 15% of patients. These lesions could be distinguished from choroidal melanoma metastases on PET/CT scans by comparing glucose uptake by the mass and adjacent normal tissues and quantitatively comparing the SUVmax values.</p>
<p>One advantage of PET/CT as a screening tool for the detection of distant metastases of uveal melanoma is that it can visualize malignant lesions in multiple organs during a single whole-body scan [<a href="#b57-medscimonit-31-e949252" class="usa-link" aria-describedby="b57-medscimonit-31-e949252">57</a>]. This eliminates the need to obtain separate scans for individual body parts. Although the liver is the primary location of uveal melanoma metastases, in 20–30% of patients, concomitant metastases are also be present in other organs. Interestingly, 8.4% of patients with choroidal melanoma present with concomitant primary tumors in other locations [<a href="#b57-medscimonit-31-e949252" class="usa-link" aria-describedby="b57-medscimonit-31-e949252">57</a>]. Cohen et al [<a href="#b56-medscimonit-31-e949252" class="usa-link" aria-describedby="b56-medscimonit-31-e949252">56</a>] confirmed the role of whole-body PET/CT in detecting such concomitant malignancies in patients with uveal melanoma. In a study conducted by these authors, concomitant malignancies in the lungs, colon, breasts, adrenal glands, and thyroid were found in 9.3% of patients with choroidal melanoma. The early detection of other asymptomatic primary malignancies has a fundamental effect on patient survival. The risk of developing concomitant primary malignancies in cancer patients is twice as high as that in sex- and age-matched cancer-free controls [<a href="#b67-medscimonit-31-e949252" class="usa-link" aria-describedby="b67-medscimonit-31-e949252">67</a>]. The concomitant occurrence of some malignancies is genetically determined. For example, in patients with hereditary BAP1 cancer predisposition syndrome, uveal melanoma can co-occur with other neoplasms [<a href="#b68-medscimonit-31-e949252" class="usa-link" aria-describedby="b68-medscimonit-31-e949252">68</a>]. Thus, early detection of choroidal melanoma should not exempt physicians from evaluating patients for concomitant primary malignancies in other locations [<a href="#b57-medscimonit-31-e949252" class="usa-link" aria-describedby="b57-medscimonit-31-e949252">57</a>]. Whole-body PET/CT scans can be particularly useful in such cases.</p>
<p>Five-year overall survival rates of uveal melanoma vary between 50% and 65% [<a href="#b69-medscimonit-31-e949252" class="usa-link" aria-describedby="b69-medscimonit-31-e949252">69</a>]. Glucose metabolism in liver metastases, expressed as SUVmax and TBR, is considered an independent prognostic factor for survival. In patients with SUVmax ≥8.5, mean overall survival was estimated at 9.4 months, as compared with up to 38.4 months in those with SUVmax &lt;8.5 [<a href="#b59-medscimonit-31-e949252" class="usa-link" aria-describedby="b59-medscimonit-31-e949252">59</a>]. Similarly, the mean overall survival in patients with liver metastases and TBR &lt;1.86 was 38.5 months versus merely 13 months in those with TBR ≥1.86.</p>
<p>Strobel et al [<a href="#b63-medscimonit-31-e949252" class="usa-link" aria-describedby="b63-medscimonit-31-e949252">63</a>] compared PET/CT results in patients with liver metastases of choroidal and cutaneous melanomas. The mean SUVmax for uveal melanoma liver metastases was significantly lower than that for cutaneous melanoma metastases to the liver (3.5 vs 6.6). However, histological analysis revealed no differences in glucose transporter-1 (GLUT-1) expression between choroidal and cutaneous melanoma metastases. The authors of the study did not speculate on the mechanism by which FDG uptake in uveal melanoma metastases was significantly lower than that in cutaneous melanoma metastases. Interestingly, in the same study, PET/CT detected extra-hepatic metastases in 36% of patients with uveal melanoma and in 86% of patients with cutaneous melanoma [<a href="#b63-medscimonit-31-e949252" class="usa-link" aria-describedby="b63-medscimonit-31-e949252">63</a>].</p></section></section><section id="sec22"><h2 class="pmc_sec_title">Monitoring of Treatment Outcomes in Posterior Uveal Melanoma with PET/CT</h2>
<section id="sec23"><h3 class="pmc_sec_title">Method of Uveal Melanoma Treatment</h3>
<p>The choice of treatment method for uveal melanoma depends on the tumor size, location within the eye, especially in relation to the macula and optic disc, concomitant complications, visual acuity in the affected eye, and the condition of the fellow eye. Additionally, patient age and general condition are important factors that should be considered. Currently available treatment options for uveal melanoma include radiotherapy (brachytherapy and irradiation with charged elementary particles), transpupillary thermotherapy, tumor resection (endo-resection or exo-resection with trans-scleral excision of the tumor), enucleation, and orbital exenteration [<a href="#b70-medscimonit-31-e949252" class="usa-link" aria-describedby="b70-medscimonit-31-e949252">70</a>].</p>
<p>Brachytherapy is the most commonly used treatment for this condition. In patients treated with this method, a radioactive plaque containing radionuclides is sewn onto the surface of the sclera based on the tumor, leaving a 2-mm margin of normal tissue. Plaques often contain iodine-125 (I-125) or ruthenium-106 (Ru-106) isotopes. Ruthenium undergoes beta-radioactive decay and is used to treat tumors with a thickness of no greater than 5–6 mm. Iodine emits gamma radiation and has applications in the treatment of thick tumors. The effect of brachytherapy is associated with the destruction of DNA in cancer cells, which eventually leads to the annihilation of cancer cells, with concomitant fibrosis and obliteration of intrinsic tumor vessels [<a href="#b71-medscimonit-31-e949252" class="usa-link" aria-describedby="b71-medscimonit-31-e949252">71</a>].</p>
<p>Another currently available treatment option is the irradiation of melanoma with a significant amount of energy emitted by charged elementary particles, protons, or helium ions. Tumor cells can also be destroyed by a diode laser with an 810-nm wavelength during a procedure referred to as transpupillary thermotherapy. The laser beam heats the tumor tissues to 45–60°C, which leads to direct injury of the cells and blood vessels and disruption of cellular enzymatic systems. Because transpupillary thermotherapy causes necrosis of tissues 3–4 mm in depth in the tumor, this method is used to treat thinner melanomas. In thicker tumors, transpupillary thermotherapy produces optimal effects when combined with brachytherapy in the so-called “sandwich method”. Photodynamic therapy, with indocyanine green as a photosensitizing agent can be used to treat smaller melanomas or as an adjuvant treatment after brachytherapy [<a href="#b70-medscimonit-31-e949252" class="usa-link" aria-describedby="b70-medscimonit-31-e949252">70</a>].</p>
<p>Tumors that are not eligible for conservative management are qualified for surgical treatment using local resection. Surgical treatment of advanced uveal melanomas may require enucleation, and orbital exenteration is the only option for cases with extra-orbital spread.</p>
<p>Monitoring therapeutic outcomes and tumor regression play key roles in assessing the effectiveness of treatment. Radiotherapy, the most common treatment modality, results in tumor shrinkage, scarification, microvasculature reduction, and retinochoroidal atrophy around the tumor base.</p></section><section id="sec24"><h3 class="pmc_sec_title">Monitoring of Chemotherapy in Uveal Melanoma with PET/CT</h3>
<p>According to Orcurto et al [<a href="#b72-medscimonit-31-e949252" class="usa-link" aria-describedby="b72-medscimonit-31-e949252">72</a>], the ratio of lesion SUVmax to liver SUVmax decreased considerably during chemotherapy for metastatic uveal melanomas with a stable diameter of metastatic foci on MRI, but the growing size of the metastatic foci on MRI was associated with an increase in this ratio. These findings suggest that <sup>18</sup>F-FDG-PET/CT may be helpful for early monitoring of treatment responses. Response to the treatment is assessed with the Response Evaluation Criteria in Solid Tumor (RECIST) criteria [<a href="#b73-medscimonit-31-e949252" class="usa-link" aria-describedby="b73-medscimonit-31-e949252">73</a>]. In line with these criteria, therapeutic response is defined as the complete disappearance of metastases or at least a 30% decrease in the sum of the longest diameters of metastatic lesions. Patients who developed new metastases and those in whom the sum of the longest lesion diameters decreased by less than 30% were considered non-responders. On PET/CT scans, a lack of response to therapy is defined as an increase in FDG uptake in pre-existing metastases or new metastases, or a lack of a significant decrease in FDG uptake in pre-existing lesions. Response to chemotherapy is defined as a decrease in the size and FDG uptake of the lesions by more than 30% or complete disappearance of pathological FDG uptake [<a href="#b74-medscimonit-31-e949252" class="usa-link" aria-describedby="b74-medscimonit-31-e949252">74</a>]. The correct identification of responders and non-responders might contribute to optimizing the therapeutic approach, primarily regarding adverse effects and treatment costs. According to Strobel et al [<a href="#b74-medscimonit-31-e949252" class="usa-link" aria-describedby="b74-medscimonit-31-e949252">74</a>], a clear relationship exists between overall survival (OS) and progression-free survival (PFS) in patients with stage IV uveal melanoma and PET/CT evidence of treatment response or lack thereof. The OS of PET/CT responders to chemotherapy was markedly longer, with the proportion of those surviving for 1 year being 80% versus 40% in PET/CT non-responders. The mean OS in PET/CT responders was 18 months (range, 14–28) versus 11 months in PET/CT non-responders, whereas the mean PFS was 9 and 3 months, respectively. Importantly, neither OS nor PFS correlated with the levels of the S-100B marker, which suggests that PET/CT is superior as a measure of response to chemotherapy. Additionally, serum S-100B yielded one-third of the false negatives as a marker of the overall treatment response in metastatic uveal melanoma [<a href="#b75-medscimonit-31-e949252" class="usa-link" aria-describedby="b75-medscimonit-31-e949252">75</a>]. The analysis of mean pre- and post-chemotherapy SUVmax values in patients with stage IV uveal melanoma decreased from 6.8 at baseline to 5.5 after 3 treatment cycles [<a href="#b74-medscimonit-31-e949252" class="usa-link" aria-describedby="b74-medscimonit-31-e949252">74</a>].</p></section><section id="sec25"><h3 class="pmc_sec_title">Monitoring of Brachytherapy in Uveal Melanoma with PET/CT</h3>
<p>PET/CT has also been shown to play a role in monitoring of brachytherapy outcomes. Eyes with uveal melanoma were demonstrated to have a significantly thicker choroid than non-affected eyes, with mean values of 293 μm and 242 μm, respectively [<a href="#b76-medscimonit-31-e949252" class="usa-link" aria-describedby="b76-medscimonit-31-e949252">76</a>]. Increasing choroid thickness in melanoma eyes is associated with increased perfusion, providing blood for highly metabolically active tumor cells undergoing tumorigenesis. Another explanation for the higher choroidal thickness in eyes with melanoma might be the overexpression of vascular endothelial growth factor and the resultant increase in choroid permeability, leading to fluid accumulation in this tissue. Among eyes with melanoma, those with metabolically active tumors were shown to have a substantially thicker choroid than those with metabolically inactive lesions (mean 348 μm and 280 μm, respectively). PET/CT performed 6 months after Ru-106 brachytherapy with adjuvant transpupillary thermotherapy demonstrated a statistically significant decrease in choroid thickness, by 40 μm on average [<a href="#b76-medscimonit-31-e949252" class="usa-link" aria-describedby="b76-medscimonit-31-e949252">76</a>]. The post-treatment decrease in choroidal thickness results from reduced choroidal perfusion associated with post-irradiation changes in the tumor vasculature, such as degeneration, hyalinization, necrosis, and occlusion of the vessels [<a href="#b77-medscimonit-31-e949252" class="usa-link" aria-describedby="b77-medscimonit-31-e949252">77</a>]. The decrease in choroidal perfusion and thickness is also associated with the lower metabolic activity of the tumor.</p>
<p>Lee et al [<a href="#b78-medscimonit-31-e949252" class="usa-link" aria-describedby="b78-medscimonit-31-e949252">78</a>] analyzed the use of PET/CT to evaluate uveal melanoma regression after Ru-106 brachytherapy combined with thermotherapy. Before treatment, the mean thicknesses of the metabolically active and inactive tumors were 8.8 mm and 5.0 mm, respectively. The mean tumor thickness at 3, 6, and 12 months after treatment was lower than that at baseline, with reductions of 88%, 78%, and 64%, respectively, for metabolically active melanomas, and by 95%, 89%, and 81%, respectively, for metabolically inactive lesions. The degree of tumor regression was substantially higher in metabolically active melanomas than in metabolically inactive melanomas. This suggests that metabolically active uveal melanomas are more prone to PET/CT-detectable regression in response to combined brachytherapy and thermotherapy. Thus, this imaging method appears to have value as a prognostic factor for treatment response. Finger and Chin [<a href="#b79-medscimonit-31-e949252" class="usa-link" aria-describedby="b79-medscimonit-31-e949252">79</a>] analyzed the time required to reduce the metabolic activity of choroidal melanoma to an SUV of 0 after brachytherapy. In the study group with a mean pretreatment SUVmax of 3.7, the mean time to tumor regression or lack of glucose uptake (SUV=0) was estimated to be 8 months (range, 6–18 months).</p></section></section><section id="sec26"><h2 class="pmc_sec_title">Limitations of PET/CT Imaging</h2>
<p>The high false-negative rate, corresponding to the failure to detect uveal melanoma in patients presenting with malignancy, is a serious limitation of PET/CT. False-negative results are obtained particularly often in the case of small uveal melanomas, which are, among others, associated with the low resolution of the method (3–4 mm). When examining the liver for potential metastases, one should remember that FDG uptake in that organ also reflects the physiological glucose metabolic flux in the normal liver. A normal mottled background can reduce the sensitivity of PET/CT in detecting liver pathologies [<a href="#b56-medscimonit-31-e949252" class="usa-link" aria-describedby="b56-medscimonit-31-e949252">56</a>]. Thus, even larger liver lesions may remain undetected if the physiological processes in that organ are not considered when interpreting the PET/CT results.</p>
<p>Another weakness of PET/CT in the detection of uveal melanoma metastases is the inability to visualize small or very small liver lesions, and all metastases of uveal melanoma to the abdominal and thoracic cavity, regardless of their diameter, can be detected by MRI [<a href="#b60-medscimonit-31-e949252" class="usa-link" aria-describedby="b60-medscimonit-31-e949252">60</a>,<a href="#b66-medscimonit-31-e949252" class="usa-link" aria-describedby="b66-medscimonit-31-e949252">66</a>,<a href="#b72-medscimonit-31-e949252" class="usa-link" aria-describedby="b72-medscimonit-31-e949252">72</a>]. The mean diameter of liver lesions detectable on MRI but invisible on PET/CT is 0.6 cm, whereas the mean diameter of lesions detected with both methods is 2.1 cm [<a href="#b72-medscimonit-31-e949252" class="usa-link" aria-describedby="b72-medscimonit-31-e949252">72</a>]. PET/CT can detect 79% of liver metastases with diameters equal to or greater than 1.2 cm. Metastases with diameters below 1.2 cm have significantly lower SUVmax values than those with diameters ≥1.2 cm. Although a positive correlation exists between the size of the liver lesion on MRI and SUVmax, no association was found between the SUV and the number of metastases [<a href="#b72-medscimonit-31-e949252" class="usa-link" aria-describedby="b72-medscimonit-31-e949252">72</a>]. Metabolic activity was particularly high in metastatic tumors that developed shortly after the diagnosis of uveal melanoma [<a href="#b57-medscimonit-31-e949252" class="usa-link" aria-describedby="b57-medscimonit-31-e949252">57</a>].</p>
<p>Whether irradiation during whole-body PET/CT poses a risk to patients remains debatable. The effective radiation dose of a single <sup>18</sup>F-FDG-PET/CT scan is 18–25 mSv, but it can increase to 30 mSv in the case of multiphasic abdominal and pelvic scans [<a href="#b80-medscimonit-31-e949252" class="usa-link" aria-describedby="b80-medscimonit-31-e949252">80</a>]. Such a dose is associated with a lifetime cancer risk of 0.6% [<a href="#b80-medscimonit-31-e949252" class="usa-link" aria-describedby="b80-medscimonit-31-e949252">80</a>]. Thus, one should consider whether the benefits associated with detecting metastases or concomitant asymptomatic primary malignancies in other organs and the early implementation of appropriate therapy outweigh the risk of increased radiation exposure.</p></section><section id="sec27"><h2 class="pmc_sec_title">Future Directions</h2>
<p>The future of PET/CT in ophthalmology is an interesting topic. PET/CT is inaccurate in detecting small uveal melanomas, small metastatic lesions, and tumors with low metabolic activity, yielding a large proportion of false-negative results. However, PET/CT may have applications in ophthalmological oncology if new and more specific radiotracers are introduced. Such new radiotracers targeting melanin, including radiolabeled antibodies, benzamide, and benzamide analogs, are the subject of ongoing research [<a href="#b2-medscimonit-31-e949252" class="usa-link" aria-describedby="b2-medscimonit-31-e949252">2</a>]. Although these studies dealt with cutaneous melanoma, the new radiotracers might also find applications in evaluating uveal melanoma. One new melanin-targeted radiotracer that has already been introduced to clinical practice is 5-bromo-N-(2-[diethylamino]ethyl) picolinamide labeled with <sup>18</sup>F (<sup>18</sup>F-5-FPN) [<a href="#b81-medscimonit-31-e949252" class="usa-link" aria-describedby="b81-medscimonit-31-e949252">81</a>]. Studies in mice have demonstrated that this radiotracer has a high potential for effectively detecting primary tumors and metastatic lesions with diameters of 1–2 mm. One potential drawback of <sup>18</sup>F-5-FPN is that it is metabolized in the liver, which may limit its application in the detection of metastases to this organ. The TBR value on <sup>18</sup>F-5-FPN PET was significantly higher than that on <sup>18</sup>F-FDG-PET [<a href="#b2-medscimonit-31-e949252" class="usa-link" aria-describedby="b2-medscimonit-31-e949252">2</a>]. A modified <sup>18</sup>F-5-FPN, in the form of <sup>18</sup>F-PEG3-FPN, had lower liver uptake but an equally high affinity to melanin. Clinical trials of this radiotracer in patients with suspected or confirmed uveal melanoma are planned at the end of 2023 after recruiting the study group [<a href="#b2-medscimonit-31-e949252" class="usa-link" aria-describedby="b2-medscimonit-31-e949252">2</a>]. Another substance being assessed in ongoing research is <sup>18</sup>F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide (<sup>18</sup>F-MEL050) [<a href="#b82-medscimonit-31-e949252" class="usa-link" aria-describedby="b82-medscimonit-31-e949252">82</a>]. This radiotracer was shown to distinguish between melanoma and normal adjacent tissues effectively and has a higher TBR than <sup>18</sup>F-FDG.</p>
<p>Another future direction in ophthalmological oncology might be PET/MRI, an examination that, to the best of our knowledge, has not yet been used in ophthalmology. High-contrast imaging of soft tissues, availability of various imaging sequences, simultaneous image acquisition, and low radiation doses might constitute arguments for applying PET/MRI to evaluate ocular tumors.</p>
<p>As technology continues to evolve, the role of PET/CT in the comprehensive management of eye cancer is likely to expand, offering enhanced insights into tumor characteristics and treatment outcomes. Regarding the impact of technological developments in the PET/CT field, the application of long-axial field-of-view PET/CT scanners in melanoma patients should be considered in the future [<a href="#b83-medscimonit-31-e949252" class="usa-link" aria-describedby="b83-medscimonit-31-e949252">83</a>].</p></section><section id="sec28"><h2 class="pmc_sec_title">Conclusions</h2>
<p>Although PET/CT has limited diagnostic value in the detection of posterior uveal melanomas, it is useful for detecting medium and large, dome-shaped, or mushroom-shaped melanomas. PET/CT poorly visualizes flat or diffuse lesions. PET/CT is a useful imaging technique for staging patients with choroidal melanomas.</p>
<p>The metabolic activity of uveal melanoma on PET/CT, expressed as the maximum standardized uptake value (SUVmax), correlates strongly with the tumor size. SUVmax may be considered an independent prognostic factor. High metabolic activity of the tumor or metastasis on PET/CT is associated with a poor prognosis.</p>
<p>PET/CT is a useful surveillance tool for the simultaneous detection of distant metastases of uveal melanoma in multiple organs. In patients with posterior uveal melanoma, PET/CT can play a role in monitoring treatment responses and determining whether systemic chemotherapy or local brachytherapy should be combined with thermotherapy.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn8-medscimonit-31-e949252"><p><strong>Conflict of interest:</strong> None declared</p></div>
<div class="fn p" id="fn9-medscimonit-31-e949252"><p>Publisher’s note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher</p></div>
<div class="fn p" id="fn10-medscimonit-31-e949252"><p><strong>Department and Institution Where Work Was Done:</strong> The work was done in the Department of Ophthalmology, Medical University of Białystok, Białystok, Poland.</p></div>
<div class="fn p" id="fn11-medscimonit-31-e949252"><p><strong>Financial support:</strong> None declared</p></div>
</div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="b1-medscimonit-31-e949252">
<span class="label">1.</span><cite>Kivelä T, Simpson RE, Grossniklaus HE, et al.   AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2016. Uveal melanoma; p. 8-5-817.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=AJCC%20Cancer%20Staging%20Manual&amp;author=T%20Kivel%C3%A4&amp;author=RE%20Simpson&amp;author=HE%20Grossniklaus&amp;publication_year=2016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b2-medscimonit-31-e949252">
<span class="label">2.</span><cite>Solnik M, Paduszyńska N, Czarnecka AM, et al.  Imaging of uveal melanoma-current standard and methods in development. Cancers. 2022;14:3147. doi: 10.3390/cancers14133147.</cite> [<a href="https://doi.org/10.3390/cancers14133147" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9265106/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35804919/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Imaging%20of%20uveal%20melanoma-current%20standard%20and%20methods%20in%20development&amp;author=M%20Solnik&amp;author=N%20Paduszy%C5%84ska&amp;author=AM%20Czarnecka&amp;volume=14&amp;publication_year=2022&amp;pages=3147&amp;pmid=35804919&amp;doi=10.3390/cancers14133147&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b3-medscimonit-31-e949252">
<span class="label">3.</span><cite>Hui KH, Pfeiffer ML, Esmaeli B. Value of positron emission tomography/computed tomography in diagnosis and staging of primary ocular and orbital tumors. Saudi J Ophthalmol. 2012;26:365–71. doi: 10.1016/j.sjopt.2012.08.008.</cite> [<a href="https://doi.org/10.1016/j.sjopt.2012.08.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3729316/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23961021/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Saudi%20J%20Ophthalmol&amp;title=Value%20of%20positron%20emission%20tomography/computed%20tomography%20in%20diagnosis%20and%20staging%20of%20primary%20ocular%20and%20orbital%20tumors&amp;author=KH%20Hui&amp;author=ML%20Pfeiffer&amp;author=B%20Esmaeli&amp;volume=26&amp;publication_year=2012&amp;pages=365-71&amp;pmid=23961021&amp;doi=10.1016/j.sjopt.2012.08.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b4-medscimonit-31-e949252">
<span class="label">4.</span><cite>Kalemaki MS, Karantanas AH, Exarchos D, et al.  PET/CT and PET/MRI in ophthalmic oncology (review) Int J Oncol. 2020;56:417–29. doi: 10.3892/ijo.2020.4955.</cite> [<a href="https://doi.org/10.3892/ijo.2020.4955" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6959466/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31939615/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Oncol&amp;title=PET/CT%20and%20PET/MRI%20in%20ophthalmic%20oncology%20(review)&amp;author=MS%20Kalemaki&amp;author=AH%20Karantanas&amp;author=D%20Exarchos&amp;volume=56&amp;publication_year=2020&amp;pages=417-29&amp;pmid=31939615&amp;doi=10.3892/ijo.2020.4955&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b5-medscimonit-31-e949252">
<span class="label">5.</span><cite>Jiang P, Liao SS, Lan XL, Jiang FG. Whole body positron emission tomography/computed tomography (PET/CT) in the evaluation of ophthalmic tumors. Curr Med Sci. 2018;38:310–17. doi: 10.1007/s11596-018-1880-7.</cite> [<a href="https://doi.org/10.1007/s11596-018-1880-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30074190/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Med%20Sci&amp;title=Whole%20body%20positron%20emission%20tomography/computed%20tomography%20(PET/CT)%20in%20the%20evaluation%20of%20ophthalmic%20tumors&amp;author=P%20Jiang&amp;author=SS%20Liao&amp;author=XL%20Lan&amp;author=FG%20Jiang&amp;volume=38&amp;publication_year=2018&amp;pages=310-17&amp;pmid=30074190&amp;doi=10.1007/s11596-018-1880-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b6-medscimonit-31-e949252">
<span class="label">6.</span><cite>Krantz BA, Dave N, Komatsubara KM, et al.  Uveal melanoma: Epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017;11:279–89. doi: 10.2147/OPTH.S89591.</cite> [<a href="https://doi.org/10.2147/OPTH.S89591" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5298817/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28203054/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Ophthalmol&amp;title=Uveal%20melanoma:%20Epidemiology,%20etiology,%20and%20treatment%20of%20primary%20disease&amp;author=BA%20Krantz&amp;author=N%20Dave&amp;author=KM%20Komatsubara&amp;volume=11&amp;publication_year=2017&amp;pages=279-89&amp;pmid=28203054&amp;doi=10.2147/OPTH.S89591&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b7-medscimonit-31-e949252">
<span class="label">7.</span><cite>Shields CL, Manalac J, Das C, et al.  Choroidal melanoma: Clinical features, classification, and top 10 pseudomelanomas. Curr Opin Ophthalmol. 2014;25:177–85. doi: 10.1097/ICU.0000000000000041.</cite> [<a href="https://doi.org/10.1097/ICU.0000000000000041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24614143/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Opin%20Ophthalmol&amp;title=Choroidal%20melanoma:%20Clinical%20features,%20classification,%20and%20top%2010%20pseudomelanomas&amp;author=CL%20Shields&amp;author=J%20Manalac&amp;author=C%20Das&amp;volume=25&amp;publication_year=2014&amp;pages=177-85&amp;pmid=24614143&amp;doi=10.1097/ICU.0000000000000041&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b8-medscimonit-31-e949252">
<span class="label">8.</span><cite>Branisteanu DC, Bogdanici CM, Branisteanu DE, et al.  Uveal melanoma diagnosis and current treatment options (review) Exp Ther Med. 2021;22:1428. doi: 10.3892/etm.2021.10863.</cite> [<a href="https://doi.org/10.3892/etm.2021.10863" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8543295/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34707709/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Exp%20Ther%20Med&amp;title=Uveal%20melanoma%20diagnosis%20and%20current%20treatment%20options%20(review)&amp;author=DC%20Branisteanu&amp;author=CM%20Bogdanici&amp;author=DE%20Branisteanu&amp;volume=22&amp;publication_year=2021&amp;pages=1428&amp;pmid=34707709&amp;doi=10.3892/etm.2021.10863&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b9-medscimonit-31-e949252">
<span class="label">9.</span><cite>Virgili G, Gatta G, Ciccolallo L, et al.  Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114:2309–15. doi: 10.1016/j.ophtha.2007.01.032.</cite> [<a href="https://doi.org/10.1016/j.ophtha.2007.01.032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17498805/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ophthalmology&amp;title=Incidence%20of%20uveal%20melanoma%20in%20Europe&amp;author=G%20Virgili&amp;author=G%20Gatta&amp;author=L%20Ciccolallo&amp;volume=114&amp;publication_year=2007&amp;pages=2309-15&amp;pmid=17498805&amp;doi=10.1016/j.ophtha.2007.01.032&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b10-medscimonit-31-e949252">
<span class="label">10.</span><cite>Shields CL, Kaliki S, Furuta M, et al.  Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012;32:1363–72. doi: 10.1097/IAE.0b013e31824d09a8.</cite> [<a href="https://doi.org/10.1097/IAE.0b013e31824d09a8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22466491/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Retina&amp;title=Clinical%20spectrum%20and%20prognosis%20of%20uveal%20melanoma%20based%20on%20age%20at%20presentation%20in%208,033%20cases&amp;author=CL%20Shields&amp;author=S%20Kaliki&amp;author=M%20Furuta&amp;volume=32&amp;publication_year=2012&amp;pages=1363-72&amp;pmid=22466491&amp;doi=10.1097/IAE.0b013e31824d09a8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b11-medscimonit-31-e949252">
<span class="label">11.</span><cite>Tarlan B, Kıratlı H. Uveal melanoma: Current trends in diagnosis and management. Turk J Ophthalmol. 2016;46:123–37. doi: 10.4274/tjo.37431.</cite> [<a href="https://doi.org/10.4274/tjo.37431" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5076295/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27800275/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Turk%20J%20Ophthalmol&amp;title=Uveal%20melanoma:%20Current%20trends%20in%20diagnosis%20and%20management&amp;author=B%20Tarlan&amp;author=H%20K%C4%B1ratl%C4%B1&amp;volume=46&amp;publication_year=2016&amp;pages=123-37&amp;pmid=27800275&amp;doi=10.4274/tjo.37431&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b12-medscimonit-31-e949252">
<span class="label">12.</span><cite>Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881–85. doi: 10.1016/j.ophtha.2011.01.040.</cite> [<a href="https://doi.org/10.1016/j.ophtha.2011.01.040" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21704381/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ophthalmology&amp;title=Uveal%20melanoma:%20trends%20in%20incidence,%20treatment,%20and%20survival&amp;author=AD%20Singh&amp;author=ME%20Turell&amp;author=AK%20Topham&amp;volume=118&amp;publication_year=2011&amp;pages=1881-85&amp;pmid=21704381&amp;doi=10.1016/j.ophtha.2011.01.040&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b13-medscimonit-31-e949252">
<span class="label">13.</span><cite>Al-Jamal RT, Cassoux N, Desjardins L, et al.  The pediatric choroidal and ciliary body melanoma study. A survey by the European ophthalmic oncology group. Ophthalmology. 2016;123:898–907. doi: 10.1016/j.ophtha.2015.12.024.</cite> [<a href="https://doi.org/10.1016/j.ophtha.2015.12.024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26854035/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ophthalmology&amp;title=The%20pediatric%20choroidal%20and%20ciliary%20body%20melanoma%20study.%20A%20survey%20by%20the%20European%20ophthalmic%20oncology%20group&amp;author=RT%20Al-Jamal&amp;author=N%20Cassoux&amp;author=L%20Desjardins&amp;volume=123&amp;publication_year=2016&amp;pages=898-907&amp;pmid=26854035&amp;doi=10.1016/j.ophtha.2015.12.024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b14-medscimonit-31-e949252">
<span class="label">14.</span><cite>Soliman N, Mamdouh D, Elkordi A. Choroidal melanoma: A mini review. Medicines. 2023;10:11. doi: 10.3390/medicines10010011.</cite> [<a href="https://doi.org/10.3390/medicines10010011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9863301/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36662495/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medicines&amp;title=Choroidal%20melanoma:%20A%20mini%20review&amp;author=N%20Soliman&amp;author=D%20Mamdouh&amp;author=A%20Elkordi&amp;volume=10&amp;publication_year=2023&amp;pages=11&amp;pmid=36662495&amp;doi=10.3390/medicines10010011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b15-medscimonit-31-e949252">
<span class="label">15.</span><cite>Violanti SS, Bononi I, Gallenga CE, et al.  New insights into molecular oncogenesis and therapy of uveal melanoma. Cancers. 2019;11:694. doi: 10.3390/cancers11050694.</cite> [<a href="https://doi.org/10.3390/cancers11050694" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6562554/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31109147/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=New%20insights%20into%20molecular%20oncogenesis%20and%20therapy%20of%20uveal%20melanoma&amp;author=SS%20Violanti&amp;author=I%20Bononi&amp;author=CE%20Gallenga&amp;volume=11&amp;publication_year=2019&amp;pages=694&amp;pmid=31109147&amp;doi=10.3390/cancers11050694&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b16-medscimonit-31-e949252">
<span class="label">16.</span><cite>Xia F, Yu Z, Deng A, Gao G. Identification of molecular subtyping system and four-gene prognostic signature with immune-related genes for uveal melanoma. Exp Biol Med. 2022;247:246–62. doi: 10.1177/15353702211053801.</cite> [<a href="https://doi.org/10.1177/15353702211053801" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8851532/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34743576/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Exp%20Biol%20Med&amp;title=Identification%20of%20molecular%20subtyping%20system%20and%20four-gene%20prognostic%20signature%20with%20immune-related%20genes%20for%20uveal%20melanoma&amp;author=F%20Xia&amp;author=Z%20Yu&amp;author=A%20Deng&amp;author=G%20Gao&amp;volume=247&amp;publication_year=2022&amp;pages=246-62&amp;pmid=34743576&amp;doi=10.1177/15353702211053801&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b17-medscimonit-31-e949252">
<span class="label">17.</span><cite>Edge SB.  Malignant melanoma of the uvea. In: Edgs SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010. pp. 547–53.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=AJCC%20Cancer%20Staging%20Manual&amp;author=SB%20Edge&amp;publication_year=2010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b18-medscimonit-31-e949252">
<span class="label">18.</span><cite>Shields CL, Furuta M, Thangappan A, et al.  Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127:989–98. doi: 10.1001/archophthalmol.2009.208.</cite> [<a href="https://doi.org/10.1001/archophthalmol.2009.208" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19667335/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Ophthalmol&amp;title=Metastasis%20of%20uveal%20melanoma%20millimeter-by-millimeter%20in%208033%20consecutive%20eyes&amp;author=CL%20Shields&amp;author=M%20Furuta&amp;author=A%20Thangappan&amp;volume=127&amp;publication_year=2009&amp;pages=989-98&amp;pmid=19667335&amp;doi=10.1001/archophthalmol.2009.208&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b19-medscimonit-31-e949252">
<span class="label">19.</span><cite>Smidt-Nielsen I, Bagger M, Heegaard S, et al.  Posterior uveal melanoma incidence and survival by AJCC tumour size in a 7-year nationwide cohort. Acta Ophthalmol. 2021;99:e1474–e82. doi: 10.1111/aos.14847.</cite> [<a href="https://doi.org/10.1111/aos.14847" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9543793/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33738986/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Ophthalmol&amp;title=Posterior%20uveal%20melanoma%20incidence%20and%20survival%20by%20AJCC%20tumour%20size%20in%20a%207-year%20nationwide%20cohort&amp;author=I%20Smidt-Nielsen&amp;author=M%20Bagger&amp;author=S%20Heegaard&amp;volume=99&amp;publication_year=2021&amp;pages=e1474-e82&amp;pmid=33738986&amp;doi=10.1111/aos.14847&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b20-medscimonit-31-e949252">
<span class="label">20.</span><cite>Garg G, Kivelä TT, Finger PT. Patients presenting with stage IV uveal melanoma: Lessons learned. Indian J Ophthalmol. 2022;70:271–74. doi: 10.4103/ijo.IJO_1478_21.</cite> [<a href="https://doi.org/10.4103/ijo.IJO_1478_21" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8917521/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34937253/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Indian%20J%20Ophthalmol&amp;title=Patients%20presenting%20with%20stage%20IV%20uveal%20melanoma:%20Lessons%20learned&amp;author=G%20Garg&amp;author=TT%20Kivel%C3%A4&amp;author=PT%20Finger&amp;volume=70&amp;publication_year=2022&amp;pages=271-74&amp;pmid=34937253&amp;doi=10.4103/ijo.IJO_1478_21&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b21-medscimonit-31-e949252">
<span class="label">21.</span><cite>Patel M, Smyth E, Chapman PB, et al.  Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res. 2011;17:2087–100. doi: 10.1158/1078-0432.CCR-10-3169.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-10-3169" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21444680/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Therapeutic%20implications%20of%20the%20emerging%20molecular%20biology%20of%20uveal%20melanoma&amp;author=M%20Patel&amp;author=E%20Smyth&amp;author=PB%20Chapman&amp;volume=17&amp;publication_year=2011&amp;pages=2087-100&amp;pmid=21444680&amp;doi=10.1158/1078-0432.CCR-10-3169&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b22-medscimonit-31-e949252">
<span class="label">22.</span><cite>Matsuo T, Ogino Y, Ichimura K, et al.  Clinicopathological correlation for the role of fluorodeoxyglucose positron emission tomography computed tomography in detection of choroidal malignant melanoma. Int J Clin Oncol. 2014;19:230–39. doi: 10.1007/s10147-013-0538-5.</cite> [<a href="https://doi.org/10.1007/s10147-013-0538-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23456141/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Clin%20Oncol&amp;title=Clinicopathological%20correlation%20for%20the%20role%20of%20fluorodeoxyglucose%20positron%20emission%20tomography%20computed%20tomography%20in%20detection%20of%20choroidal%20malignant%20melanoma&amp;author=T%20Matsuo&amp;author=Y%20Ogino&amp;author=K%20Ichimura&amp;volume=19&amp;publication_year=2014&amp;pages=230-39&amp;pmid=23456141&amp;doi=10.1007/s10147-013-0538-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b23-medscimonit-31-e949252">
<span class="label">23.</span><cite>Bagger M, Andersen MT, Andersen KK, et al.  The prognostic effect of American Joint Committee on Cancer staging and genetic status in patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci. 2014;56:438–44. doi: 10.1167/iovs.14-15571.</cite> [<a href="https://doi.org/10.1167/iovs.14-15571" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25537201/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Invest%20Ophthalmol%20Vis%20Sci&amp;title=The%20prognostic%20effect%20of%20American%20Joint%20Committee%20on%20Cancer%20staging%20and%20genetic%20status%20in%20patients%20with%20choroidal%20and%20ciliary%20body%20melanoma&amp;author=M%20Bagger&amp;author=MT%20Andersen&amp;author=KK%20Andersen&amp;volume=56&amp;publication_year=2014&amp;pages=438-44&amp;pmid=25537201&amp;doi=10.1167/iovs.14-15571&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b24-medscimonit-31-e949252">
<span class="label">24.</span><cite>Yavuzyigitoglu S, Koopmans AE, Verdijk RM, et al.  Uveal melanomas with SF3B1 mutations: A distinct subclass associated with late-onset metastases. Ophthalmology. 2016;123:1118–28. doi: 10.1016/j.ophtha.2016.01.023.</cite> [<a href="https://doi.org/10.1016/j.ophtha.2016.01.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26923342/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ophthalmology&amp;title=Uveal%20melanomas%20with%20SF3B1%20mutations:%20A%20distinct%20subclass%20associated%20with%20late-onset%20metastases&amp;author=S%20Yavuzyigitoglu&amp;author=AE%20Koopmans&amp;author=RM%20Verdijk&amp;volume=123&amp;publication_year=2016&amp;pages=1118-28&amp;pmid=26923342&amp;doi=10.1016/j.ophtha.2016.01.023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b25-medscimonit-31-e949252">
<span class="label">25.</span><cite>Dogrusöz M, Jager MJ. Genetic prognostication in uveal melanoma. Acta Ophthalmol. 2018;96:331–47. doi: 10.1111/aos.13580.</cite> [<a href="https://doi.org/10.1111/aos.13580" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29105334/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Ophthalmol&amp;title=Genetic%20prognostication%20in%20uveal%20melanoma&amp;author=M%20Dogrus%C3%B6z&amp;author=MJ%20Jager&amp;volume=96&amp;publication_year=2018&amp;pages=331-47&amp;pmid=29105334&amp;doi=10.1111/aos.13580&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b26-medscimonit-31-e949252">
<span class="label">26.</span><cite>Walter SD, Chao DL, Feuer W, et al.  Prognostic implications of tumor diameter in association with gene expression profile for Uveal melanoma. JAMA Ophthalmol. 2016;134:734–40. doi: 10.1001/jamaophthalmol.2016.0913.</cite> [<a href="https://doi.org/10.1001/jamaophthalmol.2016.0913" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4966166/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27123792/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Ophthalmol&amp;title=Prognostic%20implications%20of%20tumor%20diameter%20in%20association%20with%20gene%20expression%20profile%20for%20Uveal%20melanoma&amp;author=SD%20Walter&amp;author=DL%20Chao&amp;author=W%20Feuer&amp;volume=134&amp;publication_year=2016&amp;pages=734-40&amp;pmid=27123792&amp;doi=10.1001/jamaophthalmol.2016.0913&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b27-medscimonit-31-e949252">
<span class="label">27.</span><cite>Papastefanou VP, Islam S, Szyszko T, et al.  Metabolic activity of primary uveal melanoma on PET/CT scan and its relationship with monosomy 3 and other prognostic factors. Br J Ophthalmol. 2014;98:1659–65. doi: 10.1136/bjophthalmol-2014-305304.</cite> [<a href="https://doi.org/10.1136/bjophthalmol-2014-305304" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4251304/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25084771/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Ophthalmol&amp;title=Metabolic%20activity%20of%20primary%20uveal%20melanoma%20on%20PET/CT%20scan%20and%20its%20relationship%20with%20monosomy%203%20and%20other%20prognostic%20factors&amp;author=VP%20Papastefanou&amp;author=S%20Islam&amp;author=T%20Szyszko&amp;volume=98&amp;publication_year=2014&amp;pages=1659-65&amp;pmid=25084771&amp;doi=10.1136/bjophthalmol-2014-305304&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b28-medscimonit-31-e949252">
<span class="label">28.</span><cite>Cassoux N, Rodrigues MJ, Plancher C, et al.  Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma. Br J Ophthalmol. 2014;98(6):769–74. doi: 10.1136/bjophthalmol-2013-303867.</cite> [<a href="https://doi.org/10.1136/bjophthalmol-2013-303867" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4033183/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24169649/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Ophthalmol&amp;title=Genome-wide%20profiling%20is%20a%20clinically%20relevant%20and%20affordable%20prognostic%20test%20in%20posterior%20uveal%20melanoma&amp;author=N%20Cassoux&amp;author=MJ%20Rodrigues&amp;author=C%20Plancher&amp;volume=98&amp;issue=6&amp;publication_year=2014&amp;pages=769-74&amp;pmid=24169649&amp;doi=10.1136/bjophthalmol-2013-303867&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b29-medscimonit-31-e949252">
<span class="label">29.</span><cite>Shields CL, Kaliki S, Furuta M, et al.  American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients. Ophthalmology. 2013;120:2066–71. doi: 10.1016/j.ophtha.2013.03.012.</cite> [<a href="https://doi.org/10.1016/j.ophtha.2013.03.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23664467/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ophthalmology&amp;title=American%20Joint%20Committee%20on%20Cancer%20classification%20of%20posterior%20uveal%20melanoma%20(tumor%20size%20category)%20predicts%20prognosis%20in%207731%20patients&amp;author=CL%20Shields&amp;author=S%20Kaliki&amp;author=M%20Furuta&amp;volume=120&amp;publication_year=2013&amp;pages=2066-71&amp;pmid=23664467&amp;doi=10.1016/j.ophtha.2013.03.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b30-medscimonit-31-e949252">
<span class="label">30.</span><cite>Rodriguez-Vidal C, Fernandez-Diaz D, Fernandez-Marta B, et al.  Treatment of metastatic uveal melanoma: Systematic review. Cancers. 2020;12:2557. doi: 10.3390/cancers12092557.</cite> [<a href="https://doi.org/10.3390/cancers12092557" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7565536/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32911759/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Treatment%20of%20metastatic%20uveal%20melanoma:%20Systematic%20review&amp;author=C%20Rodriguez-Vidal&amp;author=D%20Fernandez-Diaz&amp;author=B%20Fernandez-Marta&amp;volume=12&amp;publication_year=2020&amp;pages=2557&amp;pmid=32911759&amp;doi=10.3390/cancers12092557&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b31-medscimonit-31-e949252">
<span class="label">31.</span><cite>Frizziero L, Midena E, Trainiti S, et al.  Uveal melanoma biopsy: A review. Cancers. 2019;11:1075. doi: 10.3390/cancers11081075.</cite> [<a href="https://doi.org/10.3390/cancers11081075" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6721328/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31366043/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Uveal%20melanoma%20biopsy:%20A%20review&amp;author=L%20Frizziero&amp;author=E%20Midena&amp;author=S%20Trainiti&amp;volume=11&amp;publication_year=2019&amp;pages=1075&amp;pmid=31366043&amp;doi=10.3390/cancers11081075&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b32-medscimonit-31-e949252">
<span class="label">32.</span><cite>Obuchowska I, Konopińska J. Importance of optical coherence tomography and optical coherence tomography angiography in the imaging and differentiation of choroidal melanoma: A review. Cancers. 2022;14:3354. doi: 10.3390/cancers14143354.</cite> [<a href="https://doi.org/10.3390/cancers14143354" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9316780/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35884415/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Importance%20of%20optical%20coherence%20tomography%20and%20optical%20coherence%20tomography%20angiography%20in%20the%20imaging%20and%20differentiation%20of%20choroidal%20melanoma:%20A%20review&amp;author=I%20Obuchowska&amp;author=J%20Konopi%C5%84ska&amp;volume=14&amp;publication_year=2022&amp;pages=3354&amp;pmid=35884415&amp;doi=10.3390/cancers14143354&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b33-medscimonit-31-e949252">
<span class="label">33.</span><cite>Zanzonico P. Positron emission tomography: A review of basic principles, scanner design and performance, and current systems. Semin Nucl Med. 2004;34:87–111. doi: 10.1053/j.semnuclmed.2003.12.002.</cite> [<a href="https://doi.org/10.1053/j.semnuclmed.2003.12.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15031810/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Semin%20Nucl%20Med&amp;title=Positron%20emission%20tomography:%20A%20review%20of%20basic%20principles,%20scanner%20design%20and%20performance,%20and%20current%20systems&amp;author=P%20Zanzonico&amp;volume=34&amp;publication_year=2004&amp;pages=87-111&amp;pmid=15031810&amp;doi=10.1053/j.semnuclmed.2003.12.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b34-medscimonit-31-e949252">
<span class="label">34.</span><cite>Papathanassiou D, Bruna-Muraille C, Liehn JC, et al.  Positron emission tomography in oncology: Present and future of PET and PET/CT. Crit Rev Oncol Hematol. 2009;72:239–54. doi: 10.1016/j.critrevonc.2008.10.006.</cite> [<a href="https://doi.org/10.1016/j.critrevonc.2008.10.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19091592/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Crit%20Rev%20Oncol%20Hematol&amp;title=Positron%20emission%20tomography%20in%20oncology:%20Present%20and%20future%20of%20PET%20and%20PET/CT&amp;author=D%20Papathanassiou&amp;author=C%20Bruna-Muraille&amp;author=JC%20Liehn&amp;volume=72&amp;publication_year=2009&amp;pages=239-54&amp;pmid=19091592&amp;doi=10.1016/j.critrevonc.2008.10.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b35-medscimonit-31-e949252">
<span class="label">35.</span><cite>Mercer JR. Molecular imaging agents for clinical positron emission tomography in oncology other than fluorodeoxyglucose (FDG): Applications, limitations, and potential. J Pharm Pharm Sci. 2007;10:180–202.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/17706177/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Pharm%20Pharm%20Sci&amp;title=Molecular%20imaging%20agents%20for%20clinical%20positron%20emission%20tomography%20in%20oncology%20other%20than%20fluorodeoxyglucose%20(FDG):%20Applications,%20limitations,%20and%20potential&amp;author=JR%20Mercer&amp;volume=10&amp;publication_year=2007&amp;pages=180-202&amp;pmid=17706177&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b36-medscimonit-31-e949252">
<span class="label">36.</span><cite>Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: An overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med. 2007;37:400–19. doi: 10.1053/j.semnuclmed.2007.08.004.</cite> [<a href="https://doi.org/10.1053/j.semnuclmed.2007.08.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17920348/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Semin%20Nucl%20Med&amp;title=(18)F-labeled%20positron%20emission%20tomographic%20radiopharmaceuticals%20in%20oncology:%20An%20overview%20of%20radiochemistry%20and%20mechanisms%20of%20tumor%20localization&amp;author=S%20Vallabhajosula&amp;volume=37&amp;publication_year=2007&amp;pages=400-19&amp;pmid=17920348&amp;doi=10.1053/j.semnuclmed.2007.08.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b37-medscimonit-31-e949252">
<span class="label">37.</span><cite>Paquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of (18)F-FDG: Standardized uptake values in normal tissues. J Nucl Med. 2004;45:784–88.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/15136627/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Nucl%20Med&amp;title=Within-patient%20variability%20of%20(18)F-FDG:%20Standardized%20uptake%20values%20in%20normal%20tissues&amp;author=N%20Paquet&amp;author=A%20Albert&amp;author=J%20Foidart&amp;author=R%20Hustinx&amp;volume=45&amp;publication_year=2004&amp;pages=784-88&amp;pmid=15136627&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b38-medscimonit-31-e949252">
<span class="label">38.</span><cite>Finger PT, Chin K, Iacob CE. 18-Fluorine-labelled 2-deoxy-2-fluoro-D-glucose positron emission tomography/computed tomography standardised uptake values: A non-invasive biomarker for the risk of metastasis from choroidal melanoma. Br J Ophthalmol. 2006;90:1263–66. doi: 10.1136/bjo.2006.097949.</cite> [<a href="https://doi.org/10.1136/bjo.2006.097949" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1857459/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16837539/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Ophthalmol&amp;title=18-Fluorine-labelled%202-deoxy-2-fluoro-D-glucose%20positron%20emission%20tomography/computed%20tomography%20standardised%20uptake%20values:%20A%20non-invasive%20biomarker%20for%20the%20risk%20of%20metastasis%20from%20choroidal%20melanoma&amp;author=PT%20Finger&amp;author=K%20Chin&amp;author=CE%20Iacob&amp;volume=90&amp;publication_year=2006&amp;pages=1263-66&amp;pmid=16837539&amp;doi=10.1136/bjo.2006.097949&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b39-medscimonit-31-e949252">
<span class="label">39.</span><cite>Yamada K, Brink I, Bissé E, et al.  Factors influencing [F-18] 2-fluoro-2-deoxy-D-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity. J Dermatol. 2005;32:316–34. doi: 10.1111/j.1346-8138.2005.tb00903.x.</cite> [<a href="https://doi.org/10.1111/j.1346-8138.2005.tb00903.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16043894/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Dermatol&amp;title=Factors%20influencing%20%5BF-18%5D%202-fluoro-2-deoxy-D-glucose%20(F-18%20FDG)%20uptake%20in%20melanoma%20cells:%20the%20role%20of%20proliferation%20rate,%20viability,%20glucose%20transporter%20expression%20and%20hexokinase%20activity&amp;author=K%20Yamada&amp;author=I%20Brink&amp;author=E%20Biss%C3%A9&amp;volume=32&amp;publication_year=2005&amp;pages=316-34&amp;pmid=16043894&amp;doi=10.1111/j.1346-8138.2005.tb00903.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b40-medscimonit-31-e949252">
<span class="label">40.</span><cite>Calcagni ML, Mattoli MV, Blasi MA, et al.  A prospective analysis of 18F-FDG PET/CT in patients with uveal melanoma: Comparison between metabolic rate of glucose (MRglu) and standardized uptake value (SUV) and correlations with histopathological features. Eur J Nucl Med Mol Imaging. 2013;40:1682–91. doi: 10.1007/s00259-013-2488-6.</cite> [<a href="https://doi.org/10.1007/s00259-013-2488-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23824464/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Nucl%20Med%20Mol%20Imaging&amp;title=A%20prospective%20analysis%20of%2018F-FDG%20PET/CT%20in%20patients%20with%20uveal%20melanoma:%20Comparison%20between%20metabolic%20rate%20of%20glucose%20(MRglu)%20and%20standardized%20uptake%20value%20(SUV)%20and%20correlations%20with%20histopathological%20features&amp;author=ML%20Calcagni&amp;author=MV%20Mattoli&amp;author=MA%20Blasi&amp;volume=40&amp;publication_year=2013&amp;pages=1682-91&amp;pmid=23824464&amp;doi=10.1007/s00259-013-2488-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b41-medscimonit-31-e949252">
<span class="label">41.</span><cite>Reddy S, Kurli M, Tena LB, Finger PT. PET/CT imaging: Detection of choroidal melanoma. Br J Ophthalmol. 2005;89:1265–69. doi: 10.1136/bjo.2005.066399.</cite> [<a href="https://doi.org/10.1136/bjo.2005.066399" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1772884/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16170113/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Ophthalmol&amp;title=PET/CT%20imaging:%20Detection%20of%20choroidal%20melanoma&amp;author=S%20Reddy&amp;author=M%20Kurli&amp;author=LB%20Tena&amp;author=PT%20Finger&amp;volume=89&amp;publication_year=2005&amp;pages=1265-69&amp;pmid=16170113&amp;doi=10.1136/bjo.2005.066399&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b42-medscimonit-31-e949252">
<span class="label">42.</span><cite>Spraul CW, Lang GE, Lang GK. Value of positron emission tomography in the diagnosis of malignant ocular tumors. Ophthalmologica. 2001;215:163–68. doi: 10.1159/000050851.</cite> [<a href="https://doi.org/10.1159/000050851" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11340384/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ophthalmologica&amp;title=Value%20of%20positron%20emission%20tomography%20in%20the%20diagnosis%20of%20malignant%20ocular%20tumors&amp;author=CW%20Spraul&amp;author=GE%20Lang&amp;author=GK%20Lang&amp;volume=215&amp;publication_year=2001&amp;pages=163-68&amp;pmid=11340384&amp;doi=10.1159/000050851&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b43-medscimonit-31-e949252">
<span class="label">43.</span><cite>McCannel TA, Reddy S, Burgess BL, Auerbach M. Association of positive dual-modality positron emission tomography/computed tomography imaging of primary choroidal melanoma with chromosome 3 loss and tumor size. Retina. 2010;30:146–51. doi: 10.1097/IAE.0b013e3181b32f36.</cite> [<a href="https://doi.org/10.1097/IAE.0b013e3181b32f36" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20010323/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Retina&amp;title=Association%20of%20positive%20dual-modality%20positron%20emission%20tomography/computed%20tomography%20imaging%20of%20primary%20choroidal%20melanoma%20with%20chromosome%203%20loss%20and%20tumor%20size&amp;author=TA%20McCannel&amp;author=S%20Reddy&amp;author=BL%20Burgess&amp;author=M%20Auerbach&amp;volume=30&amp;publication_year=2010&amp;pages=146-51&amp;pmid=20010323&amp;doi=10.1097/IAE.0b013e3181b32f36&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b44-medscimonit-31-e949252">
<span class="label">44.</span><cite>Singh AD, Bhatnagar P, Bybel B. Visualization of primary uveal melanoma with PET/CT scan. Eye. 2006;20:938–40. doi: 10.1038/sj.eye.6702044.</cite> [<a href="https://doi.org/10.1038/sj.eye.6702044" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16082395/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eye&amp;title=Visualization%20of%20primary%20uveal%20melanoma%20with%20PET/CT%20scan&amp;author=AD%20Singh&amp;author=P%20Bhatnagar&amp;author=B%20Bybel&amp;volume=20&amp;publication_year=2006&amp;pages=938-40&amp;pmid=16082395&amp;doi=10.1038/sj.eye.6702044&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b45-medscimonit-31-e949252">
<span class="label">45.</span><cite>Modorati G, Lucignani G, Landoni C, et al.  Glucose metabolism and pathological findings in uveal melanoma: preliminary results. Nucl Med Commun. 1996;17:1052–56. doi: 10.1097/00006231-199612000-00009.</cite> [<a href="https://doi.org/10.1097/00006231-199612000-00009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9004302/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nucl%20Med%20Commun&amp;title=Glucose%20metabolism%20and%20pathological%20findings%20in%20uveal%20melanoma:%20preliminary%20results&amp;author=G%20Modorati&amp;author=G%20Lucignani&amp;author=C%20Landoni&amp;volume=17&amp;publication_year=1996&amp;pages=1052-56&amp;pmid=9004302&amp;doi=10.1097/00006231-199612000-00009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b46-medscimonit-31-e949252">
<span class="label">46.</span><cite>Leško MM, Jurenová D, Furda R, Greguš M. The importance of PET/CT examination in patients with malignant uveal melanoma. Česka Slov Oftalmol. 2020;1:37–44. doi: 10.31348/2020/5.</cite> [<a href="https://doi.org/10.31348/2020/5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32917093/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=%C4%8Ceska%20Slov%20Oftalmol&amp;title=The%20importance%20of%20PET/CT%20examination%20in%20patients%20with%20malignant%20uveal%20melanoma&amp;author=MM%20Le%C5%A1ko&amp;author=D%20Jurenov%C3%A1&amp;author=R%20Furda&amp;author=M%20Gregu%C5%A1&amp;volume=1&amp;publication_year=2020&amp;pages=37-44&amp;pmid=32917093&amp;doi=10.31348/2020/5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b47-medscimonit-31-e949252">
<span class="label">47.</span><cite>Faia LJ, Pulido JS, Donaldson MJ, et al.  The relationship between combined positron emission tomography/computed tomography and clinical and light microscopic findings in choroidal melanoma. Retina. 2008;28:763–69. doi: 10.1097/IAE.0b013e3181631937.</cite> [<a href="https://doi.org/10.1097/IAE.0b013e3181631937" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18463523/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Retina&amp;title=The%20relationship%20between%20combined%20positron%20emission%20tomography/computed%20tomography%20and%20clinical%20and%20light%20microscopic%20findings%20in%20choroidal%20melanoma&amp;author=LJ%20Faia&amp;author=JS%20Pulido&amp;author=MJ%20Donaldson&amp;volume=28&amp;publication_year=2008&amp;pages=763-69&amp;pmid=18463523&amp;doi=10.1097/IAE.0b013e3181631937&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b48-medscimonit-31-e949252">
<span class="label">48.</span><cite>Sumich P, Mitchell P, Wang JJ. Choroidal nevi in a white population: the Blue Mountains Eye Study. Arch Ophthalmol. 1998;116:645–50. doi: 10.1001/archopht.116.5.645.</cite> [<a href="https://doi.org/10.1001/archopht.116.5.645" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9596501/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Ophthalmol&amp;title=Choroidal%20nevi%20in%20a%20white%20population:%20the%20Blue%20Mountains%20Eye%20Study&amp;author=P%20Sumich&amp;author=P%20Mitchell&amp;author=JJ%20Wang&amp;volume=116&amp;publication_year=1998&amp;pages=645-50&amp;pmid=9596501&amp;doi=10.1001/archopht.116.5.645&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b49-medscimonit-31-e949252">
<span class="label">49.</span><cite>Shields CL, Furuta M, Mashayekhi A, et al.  Clinical spectrum of choroidal nevi based on age at presentation in 3422 consecutive eyes. Ophthalmology. 2008;115:546–552e2. doi: 10.1016/j.ophtha.2007.07.009.</cite> [<a href="https://doi.org/10.1016/j.ophtha.2007.07.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18067966/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ophthalmology&amp;title=Clinical%20spectrum%20of%20choroidal%20nevi%20based%20on%20age%20at%20presentation%20in%203422%20consecutive%20eyes&amp;author=CL%20Shields&amp;author=M%20Furuta&amp;author=A%20Mashayekhi&amp;volume=115&amp;publication_year=2008&amp;pages=546-552e2&amp;pmid=18067966&amp;doi=10.1016/j.ophtha.2007.07.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b50-medscimonit-31-e949252">
<span class="label">50.</span><cite>Chien JL, Sioufi K, Surakiatchanukul T, et al.  Choroidal nevus: A review of prevalence, features, genetics, risks, and outcomes. Curr Opin Ophthalmol. 2017;28:228–37. doi: 10.1097/ICU.0000000000000361.</cite> [<a href="https://doi.org/10.1097/ICU.0000000000000361" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28141766/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Opin%20Ophthalmol&amp;title=Choroidal%20nevus:%20A%20review%20of%20prevalence,%20features,%20genetics,%20risks,%20and%20outcomes&amp;author=JL%20Chien&amp;author=K%20Sioufi&amp;author=T%20Surakiatchanukul&amp;volume=28&amp;publication_year=2017&amp;pages=228-37&amp;pmid=28141766&amp;doi=10.1097/ICU.0000000000000361&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b51-medscimonit-31-e949252">
<span class="label">51.</span><cite>Shields CL, Shields JA, Kiratli H, et al.  Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology. 1995;102:1351–61.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/9097773/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ophthalmology&amp;title=Risk%20factors%20for%20growth%20and%20metastasis%20of%20small%20choroidal%20melanocytic%20lesions&amp;author=CL%20Shields&amp;author=JA%20Shields&amp;author=H%20Kiratli&amp;volume=102&amp;publication_year=1995&amp;pages=1351-61&amp;pmid=9097773&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b52-medscimonit-31-e949252">
<span class="label">52.</span><cite>Shields CL, Furuta M, Berman EL, et al.  Choroidal nevus transformation into melanoma: Analysis of 2514 consecutive cases. Arch Ophthalmol. 2009;127:981–87. doi: 10.1001/archophthalmol.2009.151.</cite> [<a href="https://doi.org/10.1001/archophthalmol.2009.151" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19667334/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Ophthalmol&amp;title=Choroidal%20nevus%20transformation%20into%20melanoma:%20Analysis%20of%202514%20consecutive%20cases&amp;author=CL%20Shields&amp;author=M%20Furuta&amp;author=EL%20Berman&amp;volume=127&amp;publication_year=2009&amp;pages=981-87&amp;pmid=19667334&amp;doi=10.1001/archophthalmol.2009.151&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b53-medscimonit-31-e949252">
<span class="label">53.</span><cite>Eskelin S, Pyrhönen S, Summanen P, et al.  Tumor doubling times in metastatic malignant melanoma of the uvea: Tumor progression before and after treatment. Ophthalmology. 2000;107:1443–49. doi: 10.1016/s0161-6420(00)00182-2.</cite> [<a href="https://doi.org/10.1016/s0161-6420(00)00182-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10919885/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ophthalmology&amp;title=Tumor%20doubling%20times%20in%20metastatic%20malignant%20melanoma%20of%20the%20uvea:%20Tumor%20progression%20before%20and%20after%20treatment&amp;author=S%20Eskelin&amp;author=S%20Pyrh%C3%B6nen&amp;author=P%20Summanen&amp;volume=107&amp;publication_year=2000&amp;pages=1443-49&amp;pmid=10919885&amp;doi=10.1016/s0161-6420(00)00182-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b54-medscimonit-31-e949252">
<span class="label">54.</span><cite>Diener-West M, Reynolds SM, Agugliaro DJ, et al.  Screening for metastasis from choroidal melanoma: The Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol. 2004;22:2438–44. doi: 10.1200/JCO.2004.08.194.</cite> [<a href="https://doi.org/10.1200/JCO.2004.08.194" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15197206/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Screening%20for%20metastasis%20from%20choroidal%20melanoma:%20The%20Collaborative%20Ocular%20Melanoma%20Study%20Group%20Report%2023&amp;author=M%20Diener-West&amp;author=SM%20Reynolds&amp;author=DJ%20Agugliaro&amp;volume=22&amp;publication_year=2004&amp;pages=2438-44&amp;pmid=15197206&amp;doi=10.1200/JCO.2004.08.194&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b55-medscimonit-31-e949252">
<span class="label">55.</span><cite>Carvajal RD, Schwartz GK, Tezel T, et al.  Metastatic disease from uveal melanoma: Treatment options and future prospects. Br J Ophthalmol. 2017;101:38–44. doi: 10.1136/bjophthalmol-2016-309034.</cite> [<a href="https://doi.org/10.1136/bjophthalmol-2016-309034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5256122/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27574175/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Ophthalmol&amp;title=Metastatic%20disease%20from%20uveal%20melanoma:%20Treatment%20options%20and%20future%20prospects&amp;author=RD%20Carvajal&amp;author=GK%20Schwartz&amp;author=T%20Tezel&amp;volume=101&amp;publication_year=2017&amp;pages=38-44&amp;pmid=27574175&amp;doi=10.1136/bjophthalmol-2016-309034&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b56-medscimonit-31-e949252">
<span class="label">56.</span><cite>Cohen VML, Pavlidou E, DaCosta J, et al.  Staging uveal melanoma with whole-body positron-emission tomography/computed tomography and abdominal ultrasound: Low incidence of metastatic disease, high incidence of second primary cancers. Middle East Afr J Ophthalmol. 2018;25:91–95. doi: 10.4103/meajo.MEAJO_96_18.</cite> [<a href="https://doi.org/10.4103/meajo.MEAJO_96_18" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6071338/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30122854/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Middle%20East%20Afr%20J%20Ophthalmol&amp;title=Staging%20uveal%20melanoma%20with%20whole-body%20positron-emission%20tomography/computed%20tomography%20and%20abdominal%20ultrasound:%20Low%20incidence%20of%20metastatic%20disease,%20high%20incidence%20of%20second%20primary%20cancers&amp;author=VML%20Cohen&amp;author=E%20Pavlidou&amp;author=J%20DaCosta&amp;volume=25&amp;publication_year=2018&amp;pages=91-95&amp;pmid=30122854&amp;doi=10.4103/meajo.MEAJO_96_18&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b57-medscimonit-31-e949252">
<span class="label">57.</span><cite>Freton A, Chin KJ, Raut R, et al.  Initial PET/CT staging for choroidal melanoma: AJCC correlation and second nonocular primaries in 333 patients. Eur J Ophthalmol. 2012;22:236–43. doi: 10.5301/ejo.5000049.</cite> [<a href="https://doi.org/10.5301/ejo.5000049" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21959680/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Ophthalmol&amp;title=Initial%20PET/CT%20staging%20for%20choroidal%20melanoma:%20AJCC%20correlation%20and%20second%20nonocular%20primaries%20in%20333%20patients&amp;author=A%20Freton&amp;author=KJ%20Chin&amp;author=R%20Raut&amp;volume=22&amp;publication_year=2012&amp;pages=236-43&amp;pmid=21959680&amp;doi=10.5301/ejo.5000049&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b58-medscimonit-31-e949252">
<span class="label">58.</span><cite>Nathan P, Cohen V, Coupland S, et al.  Uveal melanoma UK national guidelines. Eur J Ophthalmol. 2015;51:2404–12. doi: 10.1016/j.ejca.2015.07.013.</cite> [<a href="https://doi.org/10.1016/j.ejca.2015.07.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26278648/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Ophthalmol&amp;title=Uveal%20melanoma%20UK%20national%20guidelines&amp;author=P%20Nathan&amp;author=V%20Cohen&amp;author=S%20Coupland&amp;volume=51&amp;publication_year=2015&amp;pages=2404-12&amp;pmid=26278648&amp;doi=10.1016/j.ejca.2015.07.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b59-medscimonit-31-e949252">
<span class="label">59.</span><cite>Del Carpio LP, Algarra MA, Sabaté-Llobera A, et al.  Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis. Cancer Med. 2023;12:14062–71. doi: 10.1002/cam4.6058.</cite> [<a href="https://doi.org/10.1002/cam4.6058" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10358185/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37211960/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Med&amp;title=Differences%20in%20glucose%20metabolic%20activity%20in%20liver%20metastasis%20separates%20two%20groups%20of%20metastatic%20uveal%20melanoma%20patients%20with%20different%20prognosis&amp;author=LP%20Del%20Carpio&amp;author=MA%20Algarra&amp;author=A%20Sabat%C3%A9-Llobera&amp;volume=12&amp;publication_year=2023&amp;pages=14062-71&amp;pmid=37211960&amp;doi=10.1002/cam4.6058&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b60-medscimonit-31-e949252">
<span class="label">60.</span><cite>Li X, Wang L, Zhang L, et al.  Application of multimodal and molecular imaging techniques in the detection of choroidal melanomas. Front Oncol. 2020;10:617868. doi: 10.3389/fonc.2020.617868.</cite> [<a href="https://doi.org/10.3389/fonc.2020.617868" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7902045/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33634026/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Oncol&amp;title=Application%20of%20multimodal%20and%20molecular%20imaging%20techniques%20in%20the%20detection%20of%20choroidal%20melanomas&amp;author=X%20Li&amp;author=L%20Wang&amp;author=L%20Zhang&amp;volume=10&amp;publication_year=2020&amp;pages=617868&amp;pmid=33634026&amp;doi=10.3389/fonc.2020.617868&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b61-medscimonit-31-e949252">
<span class="label">61.</span><cite>Kurli M, Reddy S, Tena LB, Pavlick AC, Finger PT. Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. Am J Ophthalmol. 2005;140:193–99. doi: 10.1016/j.ajo.2005.02.051.</cite> [<a href="https://doi.org/10.1016/j.ajo.2005.02.051" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15992753/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Ophthalmol&amp;title=Whole%20body%20positron%20emission%20tomography/computed%20tomography%20staging%20of%20metastatic%20choroidal%20melanoma&amp;author=M%20Kurli&amp;author=S%20Reddy&amp;author=LB%20Tena&amp;author=AC%20Pavlick&amp;author=PT%20Finger&amp;volume=140&amp;publication_year=2005&amp;pages=193-99&amp;pmid=15992753&amp;doi=10.1016/j.ajo.2005.02.051&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b62-medscimonit-31-e949252">
<span class="label">62.</span><cite>Klingenstein A, Haug AR, Nentwich MM, et al.  Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma. Melanoma Res. 2010;20:511–16. doi: 10.1097/CMR.0b013e3283403d6c.</cite> [<a href="https://doi.org/10.1097/CMR.0b013e3283403d6c" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20890225/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Melanoma%20Res&amp;title=Whole-body%20F-18-fluoro-2-deoxyglucose%20positron%20emission%20tomography/computed%20tomography%20imaging%20in%20the%20follow-up%20of%20metastatic%20uveal%20melanoma&amp;author=A%20Klingenstein&amp;author=AR%20Haug&amp;author=MM%20Nentwich&amp;volume=20&amp;publication_year=2010&amp;pages=511-16&amp;pmid=20890225&amp;doi=10.1097/CMR.0b013e3283403d6c&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b63-medscimonit-31-e949252">
<span class="label">63.</span><cite>Strobel K, Bode B, Dummer R, et al.  Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. Eur J Nucl Med Mol Imaging. 2009;36:1774–82. doi: 10.1007/s00259-009-1175-0.</cite> [<a href="https://doi.org/10.1007/s00259-009-1175-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19495748/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Nucl%20Med%20Mol%20Imaging&amp;title=Limited%20value%20of%2018F-FDG%20PET/CT%20and%20S-100B%20tumour%20marker%20in%20the%20detection%20of%20liver%20metastases%20from%20uveal%20melanoma%20compared%20to%20liver%20metastases%20from%20cutaneous%20melanoma&amp;author=K%20Strobel&amp;author=B%20Bode&amp;author=R%20Dummer&amp;volume=36&amp;publication_year=2009&amp;pages=1774-82&amp;pmid=19495748&amp;doi=10.1007/s00259-009-1175-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b64-medscimonit-31-e949252">
<span class="label">64.</span><cite>Francken AB, Fulham MJ, Millward MJ, Thompson JF. Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. Eur J Surg Oncol. 2006;32:780–84. doi: 10.1016/j.ejso.2006.04.011.</cite> [<a href="https://doi.org/10.1016/j.ejso.2006.04.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16765562/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Surg%20Oncol&amp;title=Detection%20of%20metastatic%20disease%20in%20patients%20with%20uveal%20melanoma%20using%20positron%20emission%20tomography&amp;author=AB%20Francken&amp;author=MJ%20Fulham&amp;author=MJ%20Millward&amp;author=JF%20Thompson&amp;volume=32&amp;publication_year=2006&amp;pages=780-84&amp;pmid=16765562&amp;doi=10.1016/j.ejso.2006.04.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b65-medscimonit-31-e949252">
<span class="label">65.</span><cite>Servois V, Mariani P, Malhaire C, et al.  Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET) Eur J Surg Oncol. 2010;36:189–94. doi: 10.1016/j.ejso.2009.08.010.</cite> [<a href="https://doi.org/10.1016/j.ejso.2009.08.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19775851/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Surg%20Oncol&amp;title=Preoperative%20staging%20of%20liver%20metastases%20from%20uveal%20melanoma%20by%20magnetic%20resonance%20imaging%20(MRI)%20and%20fluorodeoxyglucose-positron%20emission%20tomography%20(FDG-PET)&amp;author=V%20Servois&amp;author=P%20Mariani&amp;author=C%20Malhaire&amp;volume=36&amp;publication_year=2010&amp;pages=189-94&amp;pmid=19775851&amp;doi=10.1016/j.ejso.2009.08.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b66-medscimonit-31-e949252">
<span class="label">66.</span><cite>Finger PT, Kurli M, Reddy S, et al.  Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol. 2005;89:1270–74. doi: 10.1136/bjo.2005.069823.</cite> [<a href="https://doi.org/10.1136/bjo.2005.069823" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1772897/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16170114/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Ophthalmol&amp;title=Whole%20body%20PET/CT%20for%20initial%20staging%20of%20choroidal%20melanoma&amp;author=PT%20Finger&amp;author=M%20Kurli&amp;author=S%20Reddy&amp;volume=89&amp;publication_year=2005&amp;pages=1270-74&amp;pmid=16170114&amp;doi=10.1136/bjo.2005.069823&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b67-medscimonit-31-e949252">
<span class="label">67.</span><cite>Dong C, Hemminki K. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958–1996. Int J Cancer. 2001;93:155–61. doi: 10.1002/ijc.1317.</cite> [<a href="https://doi.org/10.1002/ijc.1317" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11410860/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cancer&amp;title=Second%20primary%20neoplasms%20in%20633,964%20cancer%20patients%20in%20Sweden,%201958%E2%80%931996&amp;author=C%20Dong&amp;author=K%20Hemminki&amp;volume=93&amp;publication_year=2001&amp;pages=155-61&amp;pmid=11410860&amp;doi=10.1002/ijc.1317&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b68-medscimonit-31-e949252">
<span class="label">68.</span><cite>Pilarski R, Cebulla CM, Massengill JB, et al.  Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes Cancer. 2014;53:177–82. doi: 10.1002/gcc.22129.</cite> [<a href="https://doi.org/10.1002/gcc.22129" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4041196/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24243779/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genes%20Chromosomes%20Cancer&amp;title=Expanding%20the%20clinical%20phenotype%20of%20hereditary%20BAP1%20cancer%20predisposition%20syndrome,%20reporting%20three%20new%20cases&amp;author=R%20Pilarski&amp;author=CM%20Cebulla&amp;author=JB%20Massengill&amp;volume=53&amp;publication_year=2014&amp;pages=177-82&amp;pmid=24243779&amp;doi=10.1002/gcc.22129&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b69-medscimonit-31-e949252">
<span class="label">69.</span><cite>Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973–2013) Ocul Oncol Pathol. 2018;4:145–51. doi: 10.1159/000480640.</cite> [<a href="https://doi.org/10.1159/000480640" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5939716/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29765944/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ocul%20Oncol%20Pathol&amp;title=Uveal%20melanoma:%205-year%20update%20on%20incidence,%20treatment,%20and%20survival%20(SEER%201973%E2%80%932013)&amp;author=ME%20Aronow&amp;author=AK%20Topham&amp;author=AD%20Singh&amp;volume=4&amp;publication_year=2018&amp;pages=145-51&amp;pmid=29765944&amp;doi=10.1159/000480640&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b70-medscimonit-31-e949252">
<span class="label">70.</span><cite>Sayan M, Mamidanna S, Oncel D, et al.  Clinical management of uveal melanoma: A comprehensive review with a treatment algorithm. Radiat Oncol J. 2020;38(3):162–69. doi: 10.3857/roj.2020.00318.</cite> [<a href="https://doi.org/10.3857/roj.2020.00318" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7533402/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33012143/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiat%20Oncol%20J&amp;title=Clinical%20management%20of%20uveal%20melanoma:%20A%20comprehensive%20review%20with%20a%20treatment%20algorithm&amp;author=M%20Sayan&amp;author=S%20Mamidanna&amp;author=D%20Oncel&amp;volume=38&amp;issue=3&amp;publication_year=2020&amp;pages=162-69&amp;pmid=33012143&amp;doi=10.3857/roj.2020.00318&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b71-medscimonit-31-e949252">
<span class="label">71.</span><cite>Rusňák Š, Hecová L, Kasl Z, et al.  Therapy of uveal melanoma. A review. Cesk Slov Oftalmol. 2020;77:1–13. doi: 10.31348/2020/10.</cite> [<a href="https://doi.org/10.31348/2020/10" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33086849/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cesk%20Slov%20Oftalmol&amp;title=Therapy%20of%20uveal%20melanoma.%20A%20review&amp;author=%C5%A0%20Rus%C5%88%C3%A1k&amp;author=L%20Hecov%C3%A1&amp;author=Z%20Kasl&amp;volume=77&amp;publication_year=2020&amp;pages=1-13&amp;pmid=33086849&amp;doi=10.31348/2020/10&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b72-medscimonit-31-e949252">
<span class="label">72.</span><cite>Orcurto V, Denys A, Voelter V, et al.  18F-fluorodeoxyglucosse positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: Results from a pilot study. Melanoma Res. 2012;22:63–69. doi: 10.1097/CMR.0b013e32834d3dcb.</cite> [<a href="https://doi.org/10.1097/CMR.0b013e32834d3dcb" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22027909/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Melanoma%20Res&amp;title=18F-fluorodeoxyglucosse%20positron%20emission%20tomography/computed%20tomography%20and%20magnetic%20resonance%20imaging%20in%20patients%20with%20liver%20metastases%20from%20uveal%20melanoma:%20Results%20from%20a%20pilot%20study&amp;author=V%20Orcurto&amp;author=A%20Denys&amp;author=V%20Voelter&amp;volume=22&amp;publication_year=2012&amp;pages=63-69&amp;pmid=22027909&amp;doi=10.1097/CMR.0b013e32834d3dcb&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b73-medscimonit-31-e949252">
<span class="label">73.</span><cite>Therasse P, Arbuck SG, Eisenhauer EA, et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16. doi: 10.1093/jnci/92.3.205.</cite> [<a href="https://doi.org/10.1093/jnci/92.3.205" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10655437/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Natl%20Cancer%20Inst&amp;title=New%20guidelines%20to%20evaluate%20the%20response%20to%20treatment%20in%20solid%20tumors.%20European%20Organization%20for%20Research%20and%20Treatment%20of%20Cancer,%20National%20Cancer%20Institute%20of%20the%20United%20States,%20National%20Cancer%20Institute%20of%20Canada&amp;author=P%20Therasse&amp;author=SG%20Arbuck&amp;author=EA%20Eisenhauer&amp;volume=92&amp;publication_year=2000&amp;pages=205-16&amp;pmid=10655437&amp;doi=10.1093/jnci/92.3.205&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b74-medscimonit-31-e949252">
<span class="label">74.</span><cite>Strobel K, Dummer R, Steinert HC, et al.  Chemotherapy response assessment in stage IV melanoma patients – comparison of 18F-FDG-PET/CT, CT brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imaging. 2008;35(10):1786–95. doi: 10.1007/s00259-008-0806-1.</cite> [<a href="https://doi.org/10.1007/s00259-008-0806-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18458901/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Nucl%20Med%20Mol%20Imaging&amp;title=Chemotherapy%20response%20assessment%20in%20stage%20IV%20melanoma%20patients%20%E2%80%93%20comparison%20of%2018F-FDG-PET/CT,%20CT%20brain%20MRI,%20and%20tumormarker%20S-100B&amp;author=K%20Strobel&amp;author=R%20Dummer&amp;author=HC%20Steinert&amp;volume=35&amp;issue=10&amp;publication_year=2008&amp;pages=1786-95&amp;pmid=18458901&amp;doi=10.1007/s00259-008-0806-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b75-medscimonit-31-e949252">
<span class="label">75.</span><cite>Strobel K, Dummer R, Husarik DB, et al.  High-risk melanoma: Accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology. 2007;244:566–74. doi: 10.1148/radiol.2442061099.</cite> [<a href="https://doi.org/10.1148/radiol.2442061099" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17641374/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiology&amp;title=High-risk%20melanoma:%20Accuracy%20of%20FDG%20PET/CT%20with%20added%20CT%20morphologic%20information%20for%20detection%20of%20metastases&amp;author=K%20Strobel&amp;author=R%20Dummer&amp;author=DB%20Husarik&amp;volume=244&amp;publication_year=2007&amp;pages=566-74&amp;pmid=17641374&amp;doi=10.1148/radiol.2442061099&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b76-medscimonit-31-e949252">
<span class="label">76.</span><cite>Lee JH, Lee SC, Cho A, et al.  Association between choroidal thickness and metabolic activity on positron emission tomography in eyes with choroidal melanoma. Am J Ophthalmol. 2015;160:1111–1115e2. doi: 10.1016/j.ajo.2015.08.031.</cite> [<a href="https://doi.org/10.1016/j.ajo.2015.08.031" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26343006/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Ophthalmol&amp;title=Association%20between%20choroidal%20thickness%20and%20metabolic%20activity%20on%20positron%20emission%20tomography%20in%20eyes%20with%20choroidal%20melanoma&amp;author=JH%20Lee&amp;author=SC%20Lee&amp;author=A%20Cho&amp;volume=160&amp;publication_year=2015&amp;pages=1111-1115e2&amp;pmid=26343006&amp;doi=10.1016/j.ajo.2015.08.031&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b77-medscimonit-31-e949252">
<span class="label">77.</span><cite>Takahashi K, Kishi S, Muraoka KJ, et al.  Radiation choroidopathy with remodeling of the choroidal venous system. Am J Ophthalmol. 1998;125:367–73. doi: 10.1016/s0002-9394(99)80148-2.</cite> [<a href="https://doi.org/10.1016/s0002-9394(99)80148-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9512155/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Ophthalmol&amp;title=Radiation%20choroidopathy%20with%20remodeling%20of%20the%20choroidal%20venous%20system&amp;author=K%20Takahashi&amp;author=S%20Kishi&amp;author=KJ%20Muraoka&amp;volume=125&amp;publication_year=1998&amp;pages=367-73&amp;pmid=9512155&amp;doi=10.1016/s0002-9394(99)80148-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b78-medscimonit-31-e949252">
<span class="label">78.</span><cite>Lee CS, Lee SC, Lee K, et al.  Regression of uveal melanoma after RU-106 brachytherapy and thermotherapy based on metabolic activity measured by positron emission tomography/computed tomography. Retina. 2014;34:182–87. doi: 10.1097/IAE.0b013e31829479fb.</cite> [<a href="https://doi.org/10.1097/IAE.0b013e31829479fb" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23719400/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Retina&amp;title=Regression%20of%20uveal%20melanoma%20after%20RU-106%20brachytherapy%20and%20thermotherapy%20based%20on%20metabolic%20activity%20measured%20by%20positron%20emission%20tomography/computed%20tomography&amp;author=CS%20Lee&amp;author=SC%20Lee&amp;author=K%20Lee&amp;volume=34&amp;publication_year=2014&amp;pages=182-87&amp;pmid=23719400&amp;doi=10.1097/IAE.0b013e31829479fb&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b79-medscimonit-31-e949252">
<span class="label">79.</span><cite>Finger PT, Chin KJ. [(18)F]Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) physiologic imaging of choroidal melanoma: Before and after ophthalmic plaque radiation therapy. Int J Radiat Oncol Biol Phys. 2011;79:137–42. doi: 10.1016/j.ijrobp.2009.10.041.</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2009.10.041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20395070/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Radiat%20Oncol%20Biol%20Phys&amp;title=%5B(18)F%5DFluorodeoxyglucose%20positron%20emission%20tomography/computed%20tomography%20(PET/CT)%20physiologic%20imaging%20of%20choroidal%20melanoma:%20Before%20and%20after%20ophthalmic%20plaque%20radiation%20therapy&amp;author=PT%20Finger&amp;author=KJ%20Chin&amp;volume=79&amp;publication_year=2011&amp;pages=137-42&amp;pmid=20395070&amp;doi=10.1016/j.ijrobp.2009.10.041&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b80-medscimonit-31-e949252">
<span class="label">80.</span><cite>Huang B, Law MWM, Khong PL. Whole-body PET/CT scanning: Estimation of radiation dose and cancer risk. Radiology. 2009;251:166–174. doi: 10.1148/radiol.2511081300.</cite> [<a href="https://doi.org/10.1148/radiol.2511081300" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19251940/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiology&amp;title=Whole-body%20PET/CT%20scanning:%20Estimation%20of%20radiation%20dose%20and%20cancer%20risk&amp;author=B%20Huang&amp;author=MWM%20Law&amp;author=PL%20Khong&amp;volume=251&amp;publication_year=2009&amp;pages=166-174&amp;pmid=19251940&amp;doi=10.1148/radiol.2511081300&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b81-medscimonit-31-e949252">
<span class="label">81.</span><cite>Feng H, Xia X, Li C, et al.  Imaging malignant melanoma with (18)F-5-FPN. Eur J Nucl Med Mol Imaging. 2016;43:113–22. doi: 10.1007/s00259-015-3134-2.</cite> [<a href="https://doi.org/10.1007/s00259-015-3134-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26260649/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Nucl%20Med%20Mol%20Imaging&amp;title=Imaging%20malignant%20melanoma%20with%20(18)F-5-FPN&amp;author=H%20Feng&amp;author=X%20Xia&amp;author=C%20Li&amp;volume=43&amp;publication_year=2016&amp;pages=113-22&amp;pmid=26260649&amp;doi=10.1007/s00259-015-3134-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b82-medscimonit-31-e949252">
<span class="label">82.</span><cite>Rizzo-Padoin N, Chaussard M, Vignal N, et al.  [18F]MEL050 as a melanin-targeted PET tracer: Fully automated radiosynthesis and comparison to 18F-FDG for the detection of pigmented melanoma in mice primary subcutaneous tumors and pulmonary metastases. Nucl Med Biol. 2016;43:773–80. doi: 10.1016/j.nucmedbio.2016.08.010.</cite> [<a href="https://doi.org/10.1016/j.nucmedbio.2016.08.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27693672/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nucl%20Med%20Biol&amp;title=%5B18F%5DMEL050%20as%20a%20melanin-targeted%20PET%20tracer:%20Fully%20automated%20radiosynthesis%20and%20comparison%20to%2018F-FDG%20for%20the%20detection%20of%20pigmented%20melanoma%20in%20mice%20primary%20subcutaneous%20tumors%20and%20pulmonary%20metastases&amp;author=N%20Rizzo-Padoin&amp;author=M%20Chaussard&amp;author=N%20Vignal&amp;volume=43&amp;publication_year=2016&amp;pages=773-80&amp;pmid=27693672&amp;doi=10.1016/j.nucmedbio.2016.08.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b83-medscimonit-31-e949252">
<span class="label">83.</span><cite>Sachpekidis C, Pan L, Kopp-Schneider A, et al.  Application of the long axial field-of-view PET/CT with low-dose [18F]FDG in melanoma. Eur J Nucl Med Mol Imaging. 2023;50:1158–67. doi: 10.1007/s00259-022-06070-7.</cite> [<a href="https://doi.org/10.1007/s00259-022-06070-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9931831/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36474125/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Nucl%20Med%20Mol%20Imaging&amp;title=Application%20of%20the%20long%20axial%20field-of-view%20PET/CT%20with%20low-dose%20%5B18F%5DFDG%20in%20melanoma&amp;author=C%20Sachpekidis&amp;author=L%20Pan&amp;author=A%20Kopp-Schneider&amp;volume=50&amp;publication_year=2023&amp;pages=1158-67&amp;pmid=36474125&amp;doi=10.1007/s00259-022-06070-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Medical Science Monitor: International Medical Journal of Experimental and Clinical Research are provided here courtesy of <strong>International Scientific Information, Inc.</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.12659/MSM.949252"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/medscimonit-31-e949252.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (414.1 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12377407/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12377407/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12377407%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377407/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12377407/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12377407/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40826825/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12377407/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40826825/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12377407/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12377407/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="5sUcWLHyPXd57ZpkTXxrK7b5W9z8Uek0nMO9eDHzwPf4LKWFtI6vnGYgnKAhSOOF">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
        <script type="module" crossorigin="" src="/static/assets/math-574fdcc6.js"></script>
    
    

    </body>
</html>
